(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) **World Intellectual Property Organization**
International Bureau

(43) **International Publication Date**
28 August 2008 (28.08.2008)

PCT

(10) **International Publication Number**
WO 2008/103473 A1

(51) **International Patent Classification:**
C07K 16/24 (2006.01) ***A61P 37/06*** (2006.01)
A61K 39/395 (2006.01)

(21) **International Application Number:**
PCT/US2008/002394

(22) **International Filing Date:**
21 February 2008 (21.02.2008)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
60/891,413 23 February 2007 (23.02.2007) US

(71) **Applicant** *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **PRESTA, Leonard, G.** [US/US]; 1900 Gough Street, Apt. 206, San Francisco, California 94109 (US). **BEYER, Brian, M.** [US/US]; 4401 Central Avenue, Matawan, New Jersey 07747 (US). **INGRAM, Richard, N.** [US/US]; 1454 Graymill Drive, Scotch Plains, New Jersey 07076 (US). **ORTH, Peter** [DE/US]; 100 West 93rd Street, Apartment 8H, New York, New York 10025 (US). **LIU, Yan-hui** [US/US]; 125 Roland Road, Murray Hill, New Jersey 07974 (US).

(74) **Agent: BELLOMY, Gregory, R.**; SCHERING-PLOUGH CORPORATION, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) **Title:** ENGINEERED ANTI-IL-23P19 ANTIBODIES

(57) **Abstract:** Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.

```
                                   ---CDRH1--
7G10   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSNVMH WVKQKPGQGLEWIG
6H12   EVHLQQSGPELVKPGASVKMSCKAS GYTFNRYLIH WVKQKPGQGLEWIG
13F11  EVQLQQSGPELVKPGASVKMSCKAS GHTLTRYLMH WVQQKPGQGLEWIG
13B5   EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYLMH WVKQKPGQGLEWIG
7E2    EVQLQQSGPELVKPGASVKMSCKAS GYTFTTYLMH WVKQKPGQGLEWIG
13G1   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYLMH WVKQKPGQGLEWIG
11C10  EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYVMH WVKQKPGQGLEWIG
1E10   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
30F11  EVQLQQSGPELLKPGASVKMSCKAS AYTFTRYLIH WVKQKPRQGLEWIG
5B12   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
6H4    EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYLMH WVKQKPGQGLEWIG
9C9    EVQLQQSGPELVKPGASVRMSCKAS GYTFTSYLIH WVKQKPGQGLEWIG
11B10  EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
33D2   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYLMH WVKQKPGQGLEWIG
20A9   EVQLKQSGLEVVKPGASVKMSCKAS GYTFTAHLMH WVKQRPGQGLEWIG
22E9   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
29D5   EVQLQQSGPELVKPGASVKMSCKAS GYSFTSYVMH WVKQKPGQGLEWIG
21A10  EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLDWIG
2G12   EVQLQQSGPELVKPGASVKMSCKAS GYTFTCCILH WVKQKPGQGLEWIG
15G2   EVQLQQSGPELVKPGASVKMSCKAS GYTFTNYLMH WVKQKPGQGLEWIG
18E1   EVQLQQSGPELVKPGASVKMSCKAS GNTFTRYVMN WVKQKPGQGLEWIG
2C6    EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYLIH WVKQKPGQGLEWIG
conH   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYLMH WVKQKPGQGLEWIG
                                     R VI
V1-14  EFQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG

49A10  EVQLQQSGPELVKPGASVKISCKAS GYTFTDYYMN WVKQSHGKSLEWFG
34E4   EVQLQQSGPELVKPGASVKMSCKAS GYTFTAYNMH WVKQSHGKSLEWIG
8E9    EVQLQQSGPELVKPGASVKMSCKAS GYTFTAYLIH WVKQSHGKSLEWIG
1D6    EVQLQQSGPDLVKPGASVKMSCKAS GYTFTAYLIH WVKRSHGKSLDWIG

34F9   QVQLQQSGAELAKPGASVKLSCKAS GYTFPTFWMH WVKQRPGQGLEWIG
7D7    QVQLQQSGAELAKPGASVKLSCKAS GYTFTNYWMD WVKQRPGQGLEWIG

33B12  QVQLQQSGAELARPGASVKLSCKAS GYTFTSYSLK WVKQRTGQGLEWIG
17G8   QAQLQQSGSELARPGASVKLSCKAS GYTFTSYGIK WVKQRTGQGLEWIG
20A4   QAQLQQSGGELARPGASVKLSCKAS GYTFTSYGIK WVKQGTGQGLEWIG
20H7   QAQLQQSGGELARPGASVKLSCKAS GYTFTNYGIK WVKQRTGQGLEWIG
3C4    QVQLQQSGGELARPGASVKLSCKAS GYTFTSYGIK WVKQRFGQGLEWIG

3D7    QVQLQQSGPELVKPGASVKISCKAS GYSFTSYYIH WVKQRPGQGLEWIG

39G2   QVQLQQPGAELVRPGASVKLSCKAS GYSFTSSWMN WVKQRPGQGLEWIG
35F12  QVQLQQPGAELMRPGASVRLSCKAS GYSFTTSWMN WVKQRPGQGLEWIG

14A3   EVILVESGGGFVKPGGSLKLSCAAS GFTFSNYGMS WVRQTPDKGLEWVA
12C11  EVMLVESGGGLVKPGGSLKLSCAAS GFTFSNYGMS WVRQSPERGLEWVA

10H11  EVMLVESGGGLVKPGGSLKLSCAAS GFTFSSYSMS WVRQTPEKRLEWVA
19E9   EVMLVESGGGLVKPGGSLKLSCAAS GFTFSTYDMS WVRQTPEKRLEWVA
10G8   EVMLVESGGGLVKPGGSLKLSCAAS GFTFSSYSMS WVRQTPEKRLEWVA

16F7   EVQLVESGGDLVKPGGSLKLSCAAS GFIFNSYGMS WVRQTPDKRLEWVA
```

Figure 1A

WO 2008/103473 A1

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

ENGINEERED ANTI-IL-23p19 ANTIBODIES

FIELD OF THE INVENTION

[0001] The present invention relates generally to interleukin-23 p19 (IL-23p19)-specific antibodies and uses thereof. More specifically, the invention relates to humanized antibodies that recognize human IL-23p19 and modulate its activity, particularly in inflammatory, autoimmune and proliferative disorders.

BACKGROUND OF THE INVENTION

[0002] The immune system functions to protect individuals from infective agents, e.g., bacteria, multi-cellular organisms, and viruses, as well as from cancers. This system includes several types of lymphoid and myeloid cells such as monocytes, macrophages, dendritic cells (DCs), eosinophils, T cells, B cells, and neutrophils. These lymphoid and myeloid cells often produce signaling proteins known as cytokines. The immune response includes inflammation, i.e., the accumulation of immune cells systemically or in a particular location of the body. In response to an infective agent or foreign substance, immune cells secrete cytokines which, in turn, modulate immune cell proliferation, development, differentiation, or migration. Immune response can produce pathological consequences, e.g., when it involves excessive inflammation, as in the autoimmune disorders (see, e.g., Abbas *et al.* (eds.) (2000) *Cellular and Molecular Immunology*, W.B. Saunders Co., Philadelphia, PA; Oppenheim and Feldmann (eds.) (2001) *Cytokine Reference*, Academic Press, San Diego, CA; von Andrian and Mackay (2000) *New Engl. J. Med.* 343:1020-1034; Davidson and Diamond (2001) *New Engl. J. Med.* 345:340-350).

[0003] Interleukin-12 (IL-12) is a heterodimeric molecule composed of p35 and p40 subunits. Studies have indicated that IL-12 plays a critical role in the differentiation of naïve T cells into T-helper type 1 $CD4^+$ lymphocytes that secrete IFNγ. It has also been shown that IL-12 is essential for T cell dependent immune and inflammatory responses *in vivo*. *See, e.g.*, Cua *et al.* (2003) *Nature* 421:744-748. The IL-12 receptor is composed of IL-12β1 and IL-12β2 subunits.

[0004] Interleukin-23 (IL-23) is a heterodimeric cytokine comprised of two subunits, p19 which is unique to IL-23, and p40, which is shared with IL-12. The p19 subunit is

structurally related to IL-6, granulocyte-colony stimulating factor (G-CSF), and the p35 subunit of IL-12. IL-23 mediates signaling by binding to a heterodimeric receptor, comprised of IL-23R and IL-12β1, which is shared by the IL-12 receptor. A number of early studies demonstrated that the consequences of a genetic deficiency in p40 (p40 knockout mouse; p40KO mouse) were more severe than those found in a p35KO mouse. Some of these results were eventually explained by the discovery of IL-23, and the finding that the p40KO prevents expression of not only IL-12, but also of IL-23 (*see, e.g.*, Oppmann *et al.* (2000) *Immunity* 13:715-725; Wiekowski *et al.* (2001) *J. Immunol.* 166:7563-7570; Parham *et al.* (2002) *J. Immunol.* 168:5699-708; Frucht (2002) *Sci STKE* 2002, E1-E3; Elkins *et al.* (2002) *Infection Immunity* 70:1936-1948).

[0005] Recent studies, through the use of p40 KO mice, have shown that blockade of both IL-23 and IL-12 is an effective treatment for various inflammatory and autoimmune disorders. However, the blockade of IL-12 through p40 appears to have various systemic consequences such as increased susceptibility to opportunistic microbial infections. Bowman *et al.* (2006) *Curr. Opin. Infect. Dis.* 19:245.

[0006] Therapeutic antibodies may be used to block cytokine activity. The most significant limitation in using antibodies as a therapeutic agent *in vivo* is the immunogenicity of the antibodies. As most monoclonal antibodies are derived from rodents, repeated use in humans results in the generation of an immune response against the therapeutic antibody. Such an immune response results in a loss of therapeutic efficacy at a minimum and a potential fatal anaphylactic response at a maximum. Initial efforts to reduce the immunogenicity of rodent antibodies involved the production of chimeric antibodies, in which mouse variable regions were fused with human constant regions. Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-43. However, mice injected with hybrids of human variable regions and mouse constant regions develop a strong anti-antibody response directed against the human variable region, suggesting that the retention of the entire rodent Fv region in such chimeric antibodies may still result in unwanted immunogenicity in patients.

[0007] It is generally believed that complementarity determining region (CDR) loops of variable domains comprise the binding site of antibody molecules. Therefore, the grafting of rodent CDR loops onto human frameworks (*i.e.*, humanization) was attempted to further minimize rodent sequences. Jones *et al.* (1986) *Nature* 321:522; Verhoeyen *et al.*

(1988) *Science* 239:1534. However, CDR loop exchanges still do not uniformly result in an antibody with the same binding properties as the antibody of origin. Changes in framework residues (FR), residues involved in CDR loop support, in humanized antibodies also are required to preserve antigen binding affinity. Kabat *et al.* (1991) *J. Immunol.* 147:1709. While the use of CDR grafting and framework residue preservation in a number of humanized antibody constructs has been reported, it is difficult to predict if a particular sequence will result in the antibody with the desired binding, and sometimes biological, properties. *See, e.g.,* Queen *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:10029, Gorman *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:4181, and Hodgson (1991) *Biotechnology (NY)* 9:421-5. Moreover, most prior studies used different human sequences for animal light and heavy variable sequences, rendering the predictive nature of such studies questionable. Sequences of known antibodies have been used or, more typically, those of antibodies having known X-ray structures, antibodies NEW and KOL. *See, e.g.*, Jones *et al., supra*; Verhoeyen *et al., supra*; and Gorman *et al., supra*. Exact sequence information has been reported for a few humanized constructs. Exemplary engineered antibodies to IL-23p19 are disclosed in commonly-assigned U.S. Provisional Patent Application Nos. 60/891,409 and 60/891,413 (both filed 23 February 2007), in U.S. Patent Application Publication Nos. 2007/0009526 and 2007/0048315, and in International Patent Publication Nos. WO 2007/076524, WO 2007/024846 and WO 2007/147019..

[0008] The need exists for anti-huIL-23p19 antibodies for use, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders. Preferably, such antibodies are engineered to introduce human germline sequences to reduce immunogenicity in human subjects, e.g. in the framework regions. Preferably, such antibodies will have high affinity for huIL-23p19 and will bind with high specificity to huIL-23p19.

SUMMARY OF THE INVENTION

[0009] The present invention provides binding compounds, such as antibodies or fragments thereof, including humanized or chimeric recombinant antibodies, that bind human IL-23p19, comprising at least one antibody light chain variable region, or antigen binding fragment thereof, having at least one, two or three CDRs selected from the group consisting of SEQ ID NOs: 80-88. In one embodiment, the binding compound of the present invention comprises a light chain variable domain comprising at least one CDRL1

selected from the group consisting of SEQ ID NOs: 80-82; at least one CDRL2 selected from the group consisting of SEQ ID NOs: 83-85; and at least one CDRL3 selected from the group consisting of SEQ ID NOs: 86-88.

[0010] In one embodiment, the binding compound comprises at least one antibody heavy chain variable region, or antigen binding fragment thereof, having at least one, two or three CDRs selected from the group consisting of SEQ ID NOs: 77-79.

[0011] In some embodiments, the binding compound comprises a framework region, wherein the amino acid sequence of the framework region is all or substantially all of a human immunoglobulin amino acid sequence.

[0012] In another embodiment, the binding compound of the present invention comprises at least one, two or three light chain CDRs having the sequence of SEQ ID NOs: 80-88 or optionally a variant thereof. In one embodiment, the binding compound comprises at least one, two or three heavy chain CDRs having the sequence of SEQ ID NOs: 77-79 or optionally a variant thereof. In various embodiments the variant comprises up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more conservatively modified amino acid residues relative to the sequence of the respective SEQ ID NOs. Conservative amino acid substitutions are provided at Table 1.

[0013] In other embodiments, the binding compound comprises at least one antibody light chain variable region, or antigen binding fragment thereof, having at least one, two or three CDRs selected from the group consisting of SEQ ID NOs: 68-76. In one embodiment, the binding compound of the present invention comprises a light chain variable domain comprising at least one CDRL1 selected from the group consisting of SEQ ID NOs: 68-70, at least one CDRL2 selected from the group consisting of SEQ ID NOs: 71-73 and at least one CDRL3 selected from the group consisting of SEQ ID NOs: 74-76. In one embodiment, the binding compound comprises at least one antibody heavy chain variable region, or antigen binding fragment thereof, having at least one, two or three CDRs selected from the group consisting of SEQ ID NOs: 65-67.

[0014] In other embodiments, the binding compound of the present invention comprises at least one, two or three light chain CDRs having the sequence of SEQ ID NOs: 68-76 or a variant thereof. In another embodiment, the binding compound of the present invention comprises a light chain variable domain comprising at least one CDRL1 selected from the group consisting of SEQ ID NOs: 68-70 or a variant thereof, and at least

one CDRL2 selected from the group consisting of SEQ ID NOs: 71-73 or a variant thereof, and at least one CDRL3 selected from the group consisting of SEQ ID NOs: 74-76 or a variant thereof. In one embodiment, the binding compound of the present invention comprises at least one, two or three heavy chain CDRs having the sequence of SEQ ID NOs: 65-67 or a variant thereof. In various embodiments the variant comprises up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more conservatively modified amino acid residues relative to the sequence of the respective SEQ ID NOs.

[0015] In yet another embodiment, the binding compound of the present invention comprises at least one, two or three light chain CDRs selected from the group consisting of residues 43-53, 69-75 and 108-116 of SEQ ID NOs: 2 and 4, and at least one, two or three heavy chain CDRs selected from the group consisting of residues 45-54, 69-85 and 118-123 of SEQ ID NOs: 1 and 3.

[0016] In one embodiment, the binding compound comprises an antibody light chain variable domain having the sequence of the residues 20-129 of SEQ ID NO: 2 or 4 or a variant thereof. In one embodiment, the binding compound comprises an antibody heavy chain variable domain having the sequence of residues 20-134 of SEQ ID NO: 1 or 3 or a variant thereof. In various embodiments the variant comprises up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40 or 50 or more conservatively modified amino acid residues relative to the sequence of the respective SEQ ID NOs.

[0017] In one embodiment, the binding compound comprises an antibody light chain comprising, or consisting essentially of, the sequence of the mature form (residues 20-233) of SEQ ID NO: 2 or 4. In one embodiment, the binding compound comprises an antibody heavy chain comprising, or consisting essentially of, the sequence of the mature form (residues 20-464) of SEQ ID NO: 1 or 3.

[0018] In one embodiment, the binding compound of the present invention binds to human IL-23p19 (SEQ ID NO: 29) at an epitope comprising residues 82-95, or residues 133-140, or both. In another embodiment the IL-23p19 binding compound binds to an epitope comprising some or all of residues E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139 and L140, and optionally residues K83, F90 and L110. In various embodiments the epitope for an antibody of interest is determined by obtaining an X-ray crystal structure of an antibody:antigen complex and determining which residues on IL-23p19 are within a specified distance of residues on the antibody of interest,

wherein the specified distance is, e.g., 4Å or 5Å. In some embodiments, the epitope is defined as a stretch of 8 or more contiguous amino acid residues along the IL-23p19 sequence in which at least 50%, 70% or 85% of the residues are within the specified distance of the antibody.

[0019] In other embodiments, the present invention provides a binding compound that binds to human IL-23 and has a light chain variable domain (V_L) with at least 50%, 75%, 80%, 85%, 90% or 95% sequence homology with the residues 20-129 of SEQ ID NO: 2 or 4. In one embodiment, the present invention provides a binding compound that binds to human IL-23 and has a heavy chain variable domain (V_H) with at least 50%, 75%, 80%, 85%, 90% or 95% sequence homology with residues 20-134 of SEQ ID NO: 1 or 3.

[0020] In one embodiment, the binding compound comprises, or consists essentially of, an antibody having a light chain having the sequence of the mature form (i.e. residues 20-233) of SEQ ID NO: 2 or 4. In one embodiment, the binding compound comprises, or consists essentially of, an antibody having a heavy chain having the sequence of the mature form (i.e. residues 20-464) of SEQ ID NO: 1 or 3.

[0021] In another embodiment, the binding compound of the present invention comprises an antibody light chain variable domain comprising CDRs having the sequence of residues 24-34, 50-56 and 89-97 of SEQ ID NO: 112, or a variant thereof. In another embodiment, the binding compound comprises CDRL1 having the sequence of residues 24-34 of SEQ ID NO: 112 or a variant thereof; CDRL2 having the sequence of residues 50-56 of SEQ ID NO: 112 or a variant thereof; and CDRL3 having the sequence of residues 89-97 of SEQ ID NO: 112 or a variant thereof.

[0022] In one embodiment, the binding compound comprises an antibody heavy chain variable domain comprising three CDRs selected from the group consisting of residues 26-35, 50-66 and 99-104 of SEQ ID NO: 99 and residues 50-66 of SEQ ID NOs: 129 and 130, or a variant thereof. In another embodiment, the binding compound comprises CDRH1 having the sequence of residues 26-35 of SEQ ID NO: 99 or a variant thereof; CDRH2 having the sequence of residues 50-66 of one of SEQ ID NOs: 99, 129 or 130 or a variant thereof; and CDRH3 having the sequence of residues 99-104 of SEQ ID NO: 99 or a variant thereof.

[0023] In various embodiments the variant comprises up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more conservatively modified amino acid residues relative to the sequence of the respective SEQ ID NOs. Conservative amino acid substitutions are provided at Table 1.

[0024] In one embodiment, the binding compound comprises an antibody light chain variable domain having the sequence of SEQ ID NO: 131 or a variant thereof. In one embodiment, the binding compound comprises an antibody heavy chain variable domain having the sequence of SEQ ID NO: 129, 130, 132 or 133 or a variant thereof. In various embodiments the variant comprises up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40 or 50 or more conservatively modified amino acid residues relative to the sequence of the respective SEQ ID NOs.

[0025] In one embodiment, the binding compound comprises an antibody light chain comprising, or consisting essentially of, the sequence of SEQ ID NO: 131. In one embodiment, the binding compound comprises an antibody heavy chain comprising, or consisting essentially of, the sequence of SEQ ID NO: 129, 130, 132 or 133. In one embodiment the binding compound of the present invention binds to human IL-23p19 (SEQ ID NO: 29) at an epitope comprising residues 82-95, or residues 133-140, or both. In another embodiment the IL-23p19 binding compound binds to an epitope comprising some or all of residues E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139 and L140, and optionally residues K83, F90 and L110.

[0026] In other embodiments, the present invention provides a binding compound that binds to human IL-23 and has a light chain variable domain (V_L) with at least 50%, 75%, 80%, 85%, 90% or 95% sequence homology with SEQ ID NO: 131. In one embodiment, the present invention provides a binding compound that binds to human IL-23 and has a heavy chain variable domain (V_H) with at least 50%, 75%, 80%, 85%, 90% or 95% sequence homology with SEQ ID NO: 129, 130, 132 or 133. In one embodiment the binding compound comprises the light chain variable domain of SEQ ID NO: 131 and the heavy chain variable domain of SEQ ID NO: 132.

[0027] In one embodiment, the invention relates to antibodies that are able to block the binding of a binding compound of the present invention to human IL-23 in a cross-blocking assay. In another embodiment, the invention relates to binding compounds that are able to block IL-23-mediated activity, such activities including but not limited to, binding to its receptor and promoting the proliferation or survival of T_H17 cells.

[0028] In some embodiments, the binding compound of the present invention further comprises a heavy chain constant region, wherein the heavy chain constant region comprises a γ1, γ2, γ3, or γ4 human heavy chain constant region or a variant thereof. In various embodiments the light chain constant region comprises a lambda or a kappa human light chain constant region.

[0029] In various embodiments the binding compounds of the present invention are polyclonal, monoclonal, chimeric, humanized or fully human antibodies or fragments thereof. The present invention also contemplates that the antigen binding fragment is an antibody fragment selected from the group consisting of, e.g., Fab, Fab', Fab'-SH, Fv, scFv, $F(ab')_2$, and a diabody.

[0030] The present invention encompasses a method of suppressing an immune response in a human subject comprising administering to a subject in need thereof an antibody (or a antigen binding fragment thereof) specific for IL-23 in an amount effective to block the biological activity of IL-23. In some embodiments, the antibody specific for IL-23 is the humanized or chimeric antibody. In further embodiments, the immune response is an inflammatory response including arthritis, psoriasis, and inflammatory bowel disease. In other embodiments, the immune response is an autoimmune response, including multiple sclerosis, uveitis, systemic lupus erythematosus and diabetes. In another embodiment, the subject has cancer and the immune response is a Th17 response.

[0031] The present invention also contemplates administering an additional immunosuppressive or anti-inflammatory agent. The binding compounds of the present invention can be in a pharmaceutical composition comprising the binding compound, or antigen binding fragment thereof, in combination with a pharmaceutically acceptable carrier or diluent. In a further embodiment, the pharmaceutical composition further comprises an immunosuppressive or anti-inflammatory agent.

[0032] The present invention encompasses an isolated nucleic acid encoding the polypeptide sequence of an antibody embodiment of the binding compound of the present invention. The nucleic acid can be in an expression vector operably linked to control sequences recognized by a host cell transfected with the vector. Also encompassed is a host cell comprising the vector, and a method of producing a polypeptide comprising culturing the host cell under conditions wherein the nucleic acid sequence is expressed, thereby producing the polypeptide, and recovering the polypeptide from the host cell or medium.

[0033] In various embodiments, the invention relates to use of a binding compound of the present invention in the manufacture of medicaments for the treatment of disorders including, but not limited to, inflammatory disease, autoimmune disease, cancer, infectious disease (e.g. bacterial, mycobacterial, viral or fungal infection, including chronic infections), arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, uveitis, systemic lupus erythematosus and diabetes.

[0034] In other embodiments the invention relates to pharmaceutical compositions comprising a binding compound of the present invention for treating disorders including, but not limited to, inflammatory disease, autoimmune disease, cancer, infectious disease (e.g. bacterial, mycobacterial, viral or fungal infection, including chronic infections), arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, uveitis, systemic lupus erythematosus and diabetes.

[0035] In some embodiments, the binding compound or pharmaceutical composition of the present invention induces a prolonged period of remission from disease symptoms in a subject, such that the dosing interval can be extended to much longer than the half-life of the binding compound in the subject, for example in the treatment of a relapsing-remitting disease. In various embodiments, the interval between one administration and another is 6-, 8-, 10-, 12-, 16-, 20-, 24-, 30-weeks or longer. In other embodiments a single administration is sufficient to permanently prevent relapses.

BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figures 1A – 1C show comparisons of mouse anti-human IL-23p19 antibody clone heavy chain variable domain sequences. Sequences are provided for clones 7G10, 6H12, 13F11, 13B5, 7E2, 13G1, 11C10, 1E10, 30F11, 5B12, 6H4, 9C9, 11B10, 33D2, 20A9, 22E9, 29D5, 21A10, 2G12, 15G2, 18E1, 2C6, 49A10, 34E4, 8E9, 1D6, 34F9, 7D7, 33B12, 17G8, 20A4, 20H7, 3C4, 3D7, 39G2, 35F12, 14A3, 12C11, 10H11, 19E9, 10G8 and 16F7. CDRs are indicated. Also provided is a consensus sequence for a subset of the clones (conH), and mouse germline sequences muIGHV1-14 ("V1-14"), muIGHD-Q52 ("D-Q52"), muIGHJ2 ("J2") and muIGHJ3 ("J3"). Cross references to sequence identifiers in the Sequence Listing are provided at Table 8.

[0037] Figures 2A – 2C show comparisons of mouse anti-human IL-23p19 antibody clone light chain variable domain sequences. Sequence are provided for clones 7G10,

6H12, 33B12, 13F11, 13B5, 13G1, 11C10, 7E2, 30F11, 34E4, 6H4, 33D2, 2C6, 2G12, 1D6, 18E1, 15G2, 17G8, 20A4, 20H7, 1E10, 20A9, 22E9, 29D5, 5B12, 9C9, 11B10, 16F7, 3D7, 21A10, 14A3, 12C11, 10G8, 19E9, 10H11, 39G2, 35F12, 49A10, 34F9, 8E9, 3C4 and 7D7. CDRs are indicated. Also provided are consensus sequences for each of three subfamilies of light chain CDR sequences (conLA, conLB, conLC), as well as mouse germline sequences IGKV5-39 ("m5-39"), IGKV8-30 ("m8-30") and IGVK3-12 ("m3-12"). Cross references to sequence identifiers in the Sequence Listing are provided at Table 8.

DETAILED DESCRIPTION

[0038] As used herein, including the appended claims, the singular forms of words such as "a," "an," and "the," include their corresponding plural references unless the context clearly dictates otherwise. Table 8 below provides a listing of sequence identifiers used in this application. All references cited herein are incorporated by reference to the same extent as if each individual publication, patent application, or patent, was specifically and individually indicated to be incorporated by reference. Citation of the references herein is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents.

I. Definitions

[0039] "Activation," "stimulation," and "treatment," as it applies to cells or to receptors, may have the same meaning, e.g., activation, stimulation, or treatment of a cell or receptor with a ligand, unless indicated otherwise by the context or explicitly. "Ligand" encompasses natural and synthetic ligands, e.g., cytokines, cytokine variants, analogues, muteins, and binding compositions derived from antibodies. "Ligand" also encompasses small molecules, e.g., peptide mimetics of cytokines and peptide mimetics of antibodies. "Activation" can refer to cell activation as regulated by internal mechanisms as well as by external or environmental factors. "Response," e.g., of a cell, tissue, organ, or organism, encompasses a change in biochemical or physiological behavior, e.g., concentration, density, adhesion, or migration within a biological compartment, rate of gene expression, or state of differentiation, where the change is correlated with activation, stimulation, or treatment, or with internal mechanisms such as genetic programming.

[0040] "Activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor, to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity, to the modulation of activities of other molecules, and the like. "Activity" of a molecule may also refer to activity in modulating or maintaining cell-to-cell interactions, e.g., adhesion, or activity in maintaining a structure of a cell, e.g., cell membranes or cytoskeleton. "Activity" can also mean specific activity, e.g., [catalytic activity]/[mg protein], or [immunological activity]/[mg protein], concentration in a biological compartment, or the like. "Proliferative activity" encompasses an activity that promotes, that is necessary for, or that is specifically associated with, e.g., normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.

[0041] "Administration" and "treatment," as it applies to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, refers to contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid. "Administration" and "treatment" can refer, e.g., to therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell. "Administration" and "treatment" also means *in vitro* and *ex vivo* treatments, e.g., of a cell, by a reagent, diagnostic, binding composition, or by another cell. "Treatment," as it applies to a human, veterinary, or research subject, refers to therapeutic treatment, prophylactic or preventative measures, to research and diagnostic applications. "Treatment" as it applies to a human, veterinary, or research subject, or cell, tissue, or organ, encompasses contact of an agent with animal subject, a cell, tissue, physiological compartment, or physiological fluid. "Treatment of a cell" also encompasses situations where the agent contacts IL-23 receptor (IL-23R/IL-12Rbeta1 heterodimer), e.g., in the fluid phase or colloidal phase, but also situations where the agonist or antagonist does not contact the cell or the receptor.

[0042] As used herein, the term "antibody" refers to any form of antibody that exhibits the desired biological activity. Thus, it is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (*e.g.*, bispecific antibodies), chimeric

antibodies, humanized antibodies, fully human antibodies, etc. so long as they exhibit the desired biological activity.

[0043] As used herein, the terms "IL-23p19 binding fragment," "binding fragment thereof" or "antigen binding fragment thereof" encompass a fragment or a derivative of an antibody that still substantially retains its biological activity of inhibiting IL-23p19 activity. Therefore, the term "antibody fragment" or IL-23p19 binding fragment refers to a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', $F(ab')_2$, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, e.g., sc-Fv; and multispecific antibodies formed from antibody fragments. Typically, a binding fragment or derivative retains at least 10% of its IL-23p19 inhibitory activity. Preferably, a binding fragment or derivative retains at least 25%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% (or more) of its IL-23p19 inhibitory activity, although any binding fragment with sufficient affinity to exert the desired biological effect will be useful. It is also intended that a IL-23p19 binding fragment can include conservative amino acid substitutions that do not substantially alter its biologic activity.

[0044] The term "monoclonal antibody", as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of antibodies directed against (or specific for) different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler *et al.* (1975) *Nature* 256: 495, or may be made by recombinant DNA methods (*see, e.g.*, U.S. Pat. No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.* (1991) *Nature* 352: 624-628 and Marks *et al.* (1991) *J. Mol. Biol.* 222: 581-597, for example.

[0045] The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. U.S. Pat. No. 4,816,567; Morrison *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81: 6851-6855.

[0046] A "domain antibody" is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more V_H regions are covalently joined with a peptide linker to create a bivalent domain antibody. The two V_H regions of a bivalent domain antibody may target the same or different antigens.

[0047] A "bivalent antibody" comprises two antigen binding sites. In some instances, the two binding sites have the same antigen specificities. However, bivalent antibodies may be bispecific (see below).

[0048] As used herein, the term "single-chain Fv" or "scFv" antibody refers to antibody fragments comprising the V_H and V_L domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V_H and V_L domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun (1994) THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315.

[0049] The monoclonal antibodies herein also include camelized single domain antibodies. *See, e.g.,* Muyldermans *et al.* (2001) *Trends Biochem. Sci.* 26:230; Reichmann *et al.* (1999) *J. Immunol. Methods* 231:25; WO 94/04678; WO 94/25591; U.S. Pat. No. 6,005,079). In one embodiment, the present invention provides single domain antibodies comprising two V_H domains with modifications such that single domain antibodies are formed.

[0050] As used herein, the term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V_H) connected to a light chain variable domain (V_L) in the same polypeptide chain (V_H-V_L or

V_L-V_H). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, *e.g.*, EP 404,097; WO 93/11161; and Holliger *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90: 6444-6448. For a review of engineered antibody variants generally see Holliger and Hudson (2005) *Nat. Biotechnol.* 23:1126-1136.

[0051] As used herein, the term "humanized antibody" refers to forms of antibodies that contain sequences from non-human (*e.g.*, murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. The prefix "hum", "hu" or "h" is added to antibody clone designations when necessary to distinguish humanized antibodies (e.g. hum6H12) from parental rodent antibodies (e.g. mouse 6H12, or "m6H12"). The humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.

[0052] The antibodies of the present invention also include antibodies with modified (or blocked) Fc regions to provide altered effector functions. See, e.g., U.S. Pat. No. 5,624,821; WO2003/086310; WO2005/120571; WO2006/0057702; Presta (2006) *Adv. Drug Delivery Rev.* 58:640-656. Such modification can be used to enhance or suppress various reactions of the immune system, with possible beneficial effects in diagnosis and therapy. Alterations of the Fc region include amino acid changes (substitutions, deletions and insertions), glycosylation or deglycosylation, and adding multiple Fc. Changes to the Fc can also alter the half-life of antibodies in therapeutic antibodies, and a longer half-life would result in less frequent dosing, with the concomitant increased convenience and decreased use of material. *See* Presta (2005) *J. Allergy Clin. Immunol.* 116:731 at 734-35.

[0053] The term "fully human antibody" refers to an antibody that comprises human immunoglobulin protein sequences only. A fully human antibody may contain murine

carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell. Similarly, "mouse antibody" refers to an antibody which comprises mouse immunoglobulin sequences only. A fully human antibody may be generated in a human being, in a transgenic animal having human immunoglobulin germline sequences, by phage display or other molecular biological methods.

[0054] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody that are responsible for antigen-binding. The hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR" (*e.g.* residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3) in the light chain variable domain and residues 31-35 (CDRH1), 50-65 (CDRH2) and 95-102 (CDRH3) in the heavy chain variable domain (Kabat *et al.* (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.) and/or those residues from a "hypervariable loop" (*i.e.* residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain (Chothia and Lesk (1987) *J. Mol. Biol.* 196: 901-917). As used herein, the term "framework" or "FR" residues refers to those variable domain residues other than the hypervariable region residues defined herein as CDR residues. The residue numbering above relates to the Kabat numbering system and does not necessarily correspond in detail to the sequence numbering in the accompanying Sequence Listing. *See* Tables 2 and 3, in which sequence numbering is with reference to the Sequence Listing.

[0055] "Binding compound" refers to a molecule, small molecule, macromolecule, polypeptide, antibody or fragment or analogue thereof, or soluble receptor, capable of binding to a target. "Binding compound" also may refer to a complex of molecules, e.g., a non-covalent complex, to an ionized molecule, and to a covalently or non-covalently modified molecule, e.g., modified by phosphorylation, acylation, cross-linking, cyclization, or limited cleavage, which is capable of binding to a target. When used with reference to antibodies, the term "binding compound" refers to both antibodies and antigen binding fragments thereof. "Binding" refers to an association of the binding composition with a target where the association results in reduction in the normal Brownian motion of the binding composition, in cases where the binding composition can be dissolved or suspended in solution. "Binding composition" refers to a molecule, e.g. a binding compound, in

combination with a stabilizer, excipient, salt, buffer, solvent, or additive, capable of binding to a target.

[0056] "Conservatively modified variants" or "conservative substitution" refers to substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule, even in essential regions of the polypeptide. Such exemplary substitutions are preferably made in accordance with those set forth in Table 1 as follows:

Table 1

Exemplary Conservative Amino Acid Substitutions

Original residue	Conservative substitution
Ala (A)	Gly; Ser
Arg (R)	Lys, His
Asn (N)	Gln; His
Asp (D)	Glu; Asn
Cys (C)	Ser; Ala
Gln (Q)	Asn
Glu (E)	Asp; Gln
Gly (G)	Ala
His (H)	Asn; Gln
Ile (I)	Leu; Val
Leu (L)	Ile; Val
Lys (K)	Arg; His
Met (M)	Leu; Ile; Tyr
Phe (F)	Tyr; Met; Leu
Pro (P)	Ala
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr; Phe
Tyr (Y)	Trp; Phe
Val (V)	Ile; Leu

[0057] In addition, those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter

biological activity. *See, e.g.*, Watson *et al.* (1987) *Molecular Biology of the Gene*, The Benjamin/Cummings Pub. Co., p. 224 (4th Edition).

[0058] The phrase "consists essentially of," or variations such as "consist essentially of" or "consisting essentially of," as used throughout the specification and claims, indicate the inclusion of any recited elements or group of elements, and the optional inclusion of other elements, of similar or different nature than the recited elements, that do not materially change the basic or novel properties of the specified dosage regimen, method, or composition. As a non-limiting example, a binding compound that consists essentially of a recited amino acid sequence may also include one or more amino acids, including substitutions of one or more amino acid residues, that do not materially affect the properties of the binding compound.

[0059] "Effective amount" encompasses an amount sufficient to ameliorate or prevent a symptom or sign of the medical condition. Effective amount also means an amount sufficient to allow or facilitate diagnosis. An effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side affects. *See, e.g.*, U.S. Pat. No. 5,888,530 issued to Netti *et al.* An effective amount can be the maximal dose or dosing protocol that avoids significant side effects or toxic effects. The effect will result in an improvement of a diagnostic measure or parameter by at least 5%, usually by at least 10%, more usually at least 20%, most usually at least 30%, preferably at least 40%, more preferably at least 50%, most preferably at least 60%, ideally at least 70%, more ideally at least 80%, and most ideally at least 90%, where 100% is defined as the diagnostic parameter shown by a normal subject. *See, e.g.*, Maynard *et al.* (1996) *A Handbook of SOPs for Good Clinical Practice*, Interpharm Press, Boca Raton, FL; Dent (2001) *Good Laboratory and Good Clinical Practice*, Urch Publ., London, UK.

[0060] "Exogenous" refers to substances that are produced outside an organism, cell, or human body, depending on the context. "Endogenous" refers to substances that are produced within a cell, organism, or human body, depending on the context.

[0061] "Immune condition" or "immune disorder" encompasses, e.g., pathological inflammation, an inflammatory disorder, and an autoimmune disorder or disease. "Immune condition" also refers to infections, persistent infections, and proliferative conditions, such as cancer, tumors, and angiogenesis, including infections, tumors, and cancers that resist

eradication by the immune system. "Cancerous condition" includes, e.g., cancer, cancer cells, tumors, angiogenesis, and precancerous conditions such as dysplasia.

[0062] "Inflammatory disorder" means a disorder or pathological condition where the pathology results, in whole or in part, from, e.g., a change in number, change in rate of migration, or change in activation, of cells of the immune system. Cells of the immune system include, e.g., T cells, B cells, monocytes or macrophages, antigen presenting cells (APCs), dendritic cells, microglia, NK cells, NKT cells, neutrophils, eosinophils, mast cells, or any other cell specifically associated with the immunology, for example, cytokine-producing endothelial or epithelial cells.

[0063] An "IL-17-producing cell" means a T cell that is not a classical TH1-type T cell or classical TH2-type T cell, referred to as T_H17 cells. T_H17 cells are discussed in greater detail at Cua and Kastelein (2006) *Nat. Immunol.* 7:557-559; Tato and O'Shea (2006) *Nature* 441:166-168; Iwakura and Ishigame (2006) *J. Clin. Invest.* 116:1218-1222. "IL-17-producing cell" also means a T cell that expresses a gene or polypeptide of Table 10B of U.S. Patent Application Publication No. 2004/0219150 (e.g., mitogen responsive P-protein; chemokine ligand 2; interleukin-17 (IL-17); transcription factor RAR related; and/or suppressor of cytokine signaling 3), where expression with treatment by an IL-23 agonist is greater than treatment with an IL-12 agonist, where "greater than" is defined as follows. Expression with an IL-23 agonist is ordinarily at least 5-fold greater, typically at least 10-fold greater, more typically at least 15-fold greater, most typically at least 20-fold greater, preferably at least 25-fold greater, and most preferably at least 30-fold greater, than with IL-12 treatment. Expression can be measured, e.g., with treatment of a population of substantially pure IL-17 producing cells. A Th17 response is an immune response in which the activity and/or proliferation of Th17 cells are enhanced, typically coupled with a repressed Th1 response.

[0064] Moreover, "IL-17-producing cell" includes a progenitor or precursor cell that is committed, in a pathway of cell development or cell differentiation, to differentiating into an IL-17-producing cell, as defined above. A progenitor or precursor cell to the IL-17 producing cell can be found in a draining lymph node (DLN). Additionally, "IL-17-producing cell" encompasses an IL-17-producing cell, as defined above, that has been, e.g., activated, e.g., by a phorbol ester, ionophore, and/or carcinogen, further differentiated,

stored, frozen, desiccated, inactivated, partially degraded, e.g., by apoptosis, proteolysis, or lipid oxidation, or modified, e.g., by recombinant technology.

[0065] As used herein, the term "isolated nucleic acid molecule" refers to a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the antibody nucleic acid. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

[0066] The expression "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

[0067] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0068] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant

progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

[0069] As used herein, "polymerase chain reaction" or "PCR" refers to a procedure or technique in which minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in, *e.g.*, U.S. Pat. No. 4,683,195. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers can coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. *See generally* Mullis *et al.* (1987) *Cold Spring Harbor Symp. Quant. Biol.* 51:263; Erlich, ed., (1989) PCR TECHNOLOGY (Stockton Press, N.Y.) As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

[0070] As used herein, the term "germline sequence" refers to a sequence of unrearranged immunoglobulin DNA sequences, including rodent (e.g. mouse) and human germline sequences. Any suitable source of unrearranged immunoglobulin DNA may be used. Human germline sequences may be obtained, for example, from JOINSOLVER® germline databases on the website for the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the United States National Institutes of Health. Mouse germline sequences may be obtained, for example, as described in Giudicelli *et al.* (2005) *Nucleic Acids Res.* 33:D256-D261.

[0071] "Inhibitors" and "antagonists" or "activators" and "agonists" refer to inhibitory or activating molecules, respectively, e.g., for the activation of, e.g., a ligand, receptor, cofactor, a gene, cell, tissue, or organ. A modulator of, e.g., a gene, a receptor, a ligand, or a cell, is a molecule that alters an activity of the gene, receptor, ligand, or cell, where activity can be activated, inhibited, or altered in its regulatory properties. The modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule. Inhibitors are compounds that decrease, block, prevent, delay activation,

inactivate, desensitize, or down regulate, e.g., a gene, protein, ligand, receptor, or cell. Activators are compounds that increase, activate, facilitate, enhance activation, sensitize, or up regulate, e.g., a gene, protein, ligand, receptor, or cell. An inhibitor may also be defined as a composition that reduces, blocks, or inactivates a constitutive activity. An "agonist" is a compound that interacts with a target to cause or promote an increase in the activation of the target. An "antagonist" is a compound that opposes the actions of an agonist. An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist. An antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist.

[0072] To examine the extent of inhibition, for example, samples or assays comprising a given, e.g., protein, gene, cell, or organism, are treated with a potential activating or inhibiting agent and are compared to control samples without the agent. Control samples, i.e., not treated with agent, are assigned a relative activity value of 100%. Inhibition is achieved when the activity value relative to the control is about 90% or less, typically 85% or less, more typically 80% or less, most typically 75% or less, generally 70% or less, more generally 65% or less, most generally 60% or less, typically 55% or less, usually 50% or less, more usually 45% or less, most usually 40% or less, preferably 35% or less, more preferably 30% or less, still more preferably 25% or less, and most preferably less than 25%. Activation is achieved when the activity value relative to the control is about 110%, generally at least 120%, more generally at least 140%, more generally at least 160%, often at least 180%, more often at least 2-fold, most often at least 2.5-fold, usually at least 5-fold, more usually at least 10-fold, preferably at least 20-fold, more preferably at least 40-fold, and most preferably over 40-fold higher.

[0073] Endpoints in activation or inhibition can be monitored as follows. Activation, inhibition, and response to treatment, e.g., of a cell, physiological fluid, tissue, organ, and animal or human subject, can be monitored by an endpoint. The endpoint may comprise a predetermined quantity or percentage of, e.g., an indicia of inflammation, oncogenicity, or cell degranulation or secretion, such as the release of a cytokine, toxic oxygen, or a protease. The endpoint may comprise, e.g., a predetermined quantity of ion flux or transport; cell migration; cell adhesion; cell proliferation; potential for metastasis; cell differentiation; and change in phenotype, e.g., change in expression of gene relating to inflammation, apoptosis, transformation, cell cycle, or metastasis (see, e.g., Knight (2000)

Ann. Clin. Lab. Sci. 30:145-158; Hood and Cheresh (2002) *Nature Rev. Cancer* 2:91-100; Timme *et al.* (2003) *Curr. Drug Targets* 4:251-261; Robbins and Itzkowitz (2002) *Med. Clin. North Am.* 86:1467-1495; Grady and Markowitz (2002) *Annu. Rev. Genomics Hum. Genet.* 3:101-128; Bauer, *et al.* (2001) *Glia* 36:235-243; Stanimirovic and Satoh (2000) *Brain Pathol.* 10:113-126).

[0074] An endpoint of inhibition is generally 75% of the control or less, preferably 50% of the control or less, more preferably 25% of the control or less, and most preferably 10% of the control or less. Generally, an endpoint of activation is at least 150% the control, preferably at least two times the control, more preferably at least four times the control, and most preferably at least 10 times the control.

[0075] "Ligand" refers, e.g., to a small molecule, peptide, polypeptide, and membrane associated or membrane-bound molecule, or complex thereof, that can act as an agonist or antagonist of a receptor. "Ligand" also encompasses an agent that is not an agonist or antagonist, but that can bind to the receptor. Moreover, "ligand" includes a membrane-bound ligand that has been changed, e.g., by chemical or recombinant methods, to a soluble version of the membrane-bound ligand. By convention, where a ligand is membrane-bound on a first cell, the receptor usually occurs on a second cell. The second cell may have the same or a different identity as the first cell. A ligand or receptor may be entirely intracellular, that is, it may reside in the cytosol, nucleus, or some other intracellular compartment. The ligand or receptor may change its location, e.g., from an intracellular compartment to the outer face of the plasma membrane. The complex of a ligand and receptor is termed a "ligand receptor complex." Where a ligand and receptor are involved in a signaling pathway, the ligand occurs at an upstream position and the receptor occurs at a downstream position of the signaling pathway.

[0076] "Small molecule" is defined as a molecule with a molecular weight that is less than 10 kDa, typically less than 2 kDa, and preferably less than 1 kDa. Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing an inorganic component, molecules comprising a radioactive atom, synthetic molecules, peptide mimetics, and antibody mimetics. As a therapeutic, a small molecule may be more permeable to cells, less susceptible to degradation, and less apt to elicit an immune response than large molecules. Small molecules, such as peptide mimetics of antibodies and cytokines, as well as small molecule toxins are described. *See, e.g.*, Casset *et*

al. (2003) *Biochem. Biophys. Res. Commun.* 307:198-205; Muyldermans (2001) *J. Biotechnol.* 74:277-302; Li (2000) *Nat. Biotechnol.* 18:1251-1256; Apostolopoulos *et al.* (2002) *Curr. Med. Chem.* 9:411-420; Monfardini *et al.* (2002) *Curr. Pharm. Des.* 8:2185-2199; Domingues *et al.* (1999) *Nat. Struct. Biol.* 6:652-656; Sato and Sone (2003) *Biochem. J.* 371:603-608; U.S. Patent No. 6,326,482.

[0077] "Specifically" or "selectively" binds, when referring to a ligand/receptor, antibody/antigen, or other binding pair, indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample. As used herein, an antibody is said to bind specifically to a polypeptide *comprising* a given sequence (in this case IL-23p19) if it binds to polypeptides comprising the sequence of IL-23p19 but does not bind to proteins lacking the sequence of IL-23p19. For example, an antibody that specifically binds to a polypeptide comprising IL-23p19 may bind to a FLAG®-tagged form of IL-23p19 but will not bind to other FLAG®-tagged proteins.

[0078] The antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its antigen with an affinity that is at least two fold greater, preferably at least ten times greater, more preferably at least 20-times greater, and most preferably at least 100-times greater than the affinity with unrelated antigens. In a preferred embodiment the antibody will have an affinity that is greater than about 10^9 liters/mol, as determined, e.g., by Scatchard analysis. Munsen *et al.* (1980) *Analyt. Biochem.* 107:220-239.

[0079] As used herein, the term "immunomodulatory agent" refers to natural or synthetic agents that suppress or modulate an immune response. The immune response can be a humoral or cellular response. Immunomodulatory agents encompass immunosuppressive or anti-inflammatory agents.

[0080] "Immunosuppressive agents," "immunosuppressive drugs," or "immunosuppressants" as used herein are therapeutics that are used in immunosuppressive therapy to inhibit or prevent activity of the immune system. Clinically they are used to prevent the rejection of transplanted organs and tissues (e.g. bone marrow, heart, kidney, liver), and/or in the treatment of autoimmune diseases or diseases that are most likely of autoimmune origin (e.g. rheumatoid arthritis, myasthenia gravis, systemic lupus

erythematosus, ulcerative colitis, multiple sclerosis). Immunosuppressive drugs can be classified into four groups: glucocorticoids cytostatics; antibodies (including Biological Response Modifiers or DMARDs); drugs acting on immunophilins; other drugs, including known chemotherpeutic agents used in the treatment of proliferative disorders. For multiple sclerosis, in particular, the antibodies of the present invention can be administered in conjunction with a new class of myelin binding protein-like therapeutics, known as copaxones.

[0081] "Anti-inflammatory agents" or "anti-inflammatory drugs", is used to represent both steroidal and non-steroidal therapeutics. Steroids, also known as corticosteroids, are drugs that closely resemble cortisol, a hormone produced naturally by adrenal glands. Steroids are used as the main treatment for certain inflammatory conditions, such as: Systemic vasculitis (inflammation of blood vessels); and Myositis (inflammation of muscle). Steroids might also be used selectively to treat inflammatory conditions such as: rheumatoid arthritis (chronic inflammatory arthritis occurring in joints on both sides of the body); systemic lupus erythematosus (a generalized disease caused by abnormal immune system function); Sjögren's syndrome (chronic disorder that causes dry eyes and a dry mouth).

[0082] Non-steroidal anti-inflammatory drugs, usually abbreviated to NSAIDs, are drugs with analgesic, antipyretic and anti-inflammatory effects - they reduce pain, fever and inflammation. The term "non-steroidal" is used to distinguish these drugs from steroids, which (amongst a broad range of other effects) have a similar eicosanoid-depressing, anti-inflammatory action. NSAIDs are generally indicated for the symptomatic relief of the following conditions: rheumatoid arthritis; osteoarthritis; inflammatory arthropathies (e.g. ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome); acute gout; dysmenorrhoea; metastatic bone pain; headache and migraine; postoperative pain; mild-to-moderate pain due to inflammation and tissue injury; pyrexia; and renal colic. NSAIDs include salicylates, arlyalknoic acids, 2-arylpropionic acids (profens), N-arylanthranilic acids (fenamic acids), oxicams, coxibs, and sulphonanilides.

II. General

[0083] The present invention provides engineered anti-IL-23 antibodies and uses thereof to treat inflammatory, autoimmune, and proliferative disorders. A subset of the

antibodies disclosed herein are also disclosed in U.S. Patent Application Publication No. 2007/0048315, specifically clones 7G10, 6H12, 13F11, 13B5, 7E2, 13G1, 11C10, 1E10, 30F11, 5B12, 6H4, 9C9, 11B10, 33D2, 20A9, 22E9, 29D5, 21A10, 49A10, 34E4, 34F9, 7D7, 33B12, 3D7, 39G2, 35F12, 10H11, 19E9 and 10G8.

[0084] A number of cytokines have a role in the pathology or repair of neurological disorders. IL-6, IL-17, interferon-gamma (IFNgamma, IFN-γ), and granulocyte colony-stimulating factor (GM-CSF) have been associated with multiple sclerosis. Matusevicius *et al.* (1999) *Multiple Sclerosis* 5:101-104; Lock *et al.* (2002) *Nature Med.* 8:500-508. IL-1alpha, IL-1beta, and transforming growth factor-beta 1 (TGF-beta1) play a role in ALS, Parkinson's disease, and Alzheimer's disease. Hoozemans *et al.* (2001) *Exp. Gerontol.* 36:559-570; Griffin and Mrak (2002) *J. Leukocyte Biol.* 72:233-238; Ilzecka *et al.* (2002) *Cytokine* 20:239-243. TNF-alpha, IL-1beta, IL-6, IL-8, interferon-gamma, and IL-17 appear to modulate response to brain ischemia. *See, e.g.*, Kostulas *et al.* (1999) *Stroke* 30:2174-2179; Li *et al.* (2001) *J. Neuroimmunol.* 116:5-14. Vascular endothelial cell growth factor (VEGF) is associated with ALS. Cleveland and Rothstein (2001) *Nature* 2:806-819.

[0085] Inflammatory bowel disorders, e.g., Crohn's disease, ulcerative colitis, celiac disease, and irritable bowel syndrome, are mediated by cells of the immune system and by cytokines. For example, Crohn's disease is associated with increased IL-12 and IFNγ, while ulcerative colitis is associated with increased IL-5, IL-13, and transforming growth factor-beta (TGFbeta). IL-17 expression may also increase in Crohn's disease and ulcerative colitis. *See, e.g.,* Podolsky (2002) *New Engl. J. Med.* 347:417-429; Bouma and Strober (2003) *Nat. Rev. Immunol.* 3:521-533; Bhan *et al.* (1999) *Immunol. Rev.* 169:195-207; Hanauer (1996) *New Engl. J. Med.* 334:841-848; Green (2003) *The Lancet* 362:383-391; McManus (2003) *New Engl. J. Med.* 348:2573-2574; Horwitz and Fisher (2001) *New Engl. J. Med.* 344:1846-1850; Andoh *et al.* (2002) *Int. J. Mol. Med.* 10:631-634; Nielsen *et al.* (2003) *Scand. J. Gastroenterol.* 38:180-185; Fujino *et al.* (2003) *Gut* 52:65-70.

[0086] IL-23 receptor is a heterodimeric complex of IL-23R and IL-12Rβ1 subunits. *See* Parham *et al.* (2000) *J. Immunol.* 168:5699. IL-12 receptor is a complex of IL-12Rβ1 and IL-12Rβ2 subunits. *See* Presky *et al.* (1996) *Proc. Nat'l Acad. Sci. USA* 93:14002. IL-23R has been implicated as a critical genetic factor in the inflammatory bowel disorders Crohn's disease and ulcerative colitis. Duerr *et al.* (2006) *Sciencexpress* 26-October-2006:1. A genome-wide association study found that the gene for IL-23R was highly

associated with Crohn's disease, with an uncommon coding variant (Arg381Gln) conferring strong protection against the disease. This genetic association confirms prior biological findings (Yen *et al.* (2006) *J. Clin. Investigation* 116:1218) suggesting that IL-23 and its receptor are promising targets for new therapeutic approached to treating IBD.

[0087] Inflammatory diseases of the skin, joints, CNS, as well as proliferative disorders elicit similar immune responses, thus IL-23 blockade should provide inhibition of these immune mediated inflammatory disorders, without comprising the host ability to fight systemic infections. Antagonizing IL-23 should relieve the inflammation associated with inflammatory bowel disease, Crohn's disease, Ulcerative Colitis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, and atopic dermatitis. Use of IL-23 inhibitors will also provide inhibition of proliferative disorders, e.g., cancer and autoimmune disorders, e.g., multiple sclerosis, type I diabetes, and SLE. Descriptions of IL-23 in these various disorders can be found in the following published PCT applications: WO 04/081190; WO 04/071517; WO 00/53631; and WO 01/18051. IL-23 inhibitors may also find use in treatment of infections, including chronic infections, such as bacterial, mycobacterial, viral and fungal infections.

[0088] The p19 subunit of IL-23 is a member of the 'long chain' family of hematopoietic cytokines (Oppmann *et al.* (2000) *supra*) and comprises four packed α-helices termed A, B, C and D, with an up-up-down-down topology. The 4 helices are connected by 3 polypeptide loops. The A-B and C-D loops are modeled to be relatively long as they connect parallel helices. The short B-C loop connects the antiparallel B and C helices. The p19 subunit of IL-23 is a member of the IL-6 family of helical cytokines. This family of cytokines bind to their cognate receptors through three conserved epitopes (site I, II and III; Bravo and Heath (2000) *EMBO J.* 19:2399-2411). The p19 subunit interacts with three cytokine receptor subunits to form the competent signaling complex. When expressed in a cell, the p19 subunit first form a complex with the p40 subunit, which it shares with IL-12. As noted above, the p19p40 complex is secreted from the cell as a heterodimeric protein and is called IL-23. *See, e.g.*, Oppmann *et al.*, *supra*. The cellular receptor complex required to transduce the IL-23 signal consists of two members of the tall signaling receptor subunits of the IL-6/IL-12 family of cytokines, the IL-23-specific IL-23R (see, e.g., Parham et al. *supra*) and the IL-12Rb1, that is shared with IL-12.

[0089] Insights into the structural basis of 'long chain' cytokine/receptor recognition have shown that although large areas of protein surface are buried in formation of cytokine – receptor complexes, the affinity of the interaction is dominated by a few, often tightly clustered amino acid residues forming an energetic 'hot spot' in the center of the binding interface. The identity of the residues that dominate the binding energy of a large protein-protein interface has been termed the 'functional epitope.' The affinity of the interaction (and hence biological specificity) is consequently defined by the structural complementarity of the functional epitopes of ligand and receptor. Detailed mutagenesis studies have shown that the most significant residues that make up the functional epitopes of cytokines and receptors are hydrophobic contacts involving either non-polar side chains such as tryptophan, the aliphatic components of non-polar side chains or the polypeptide backbone. The non-polar 'core' is surrounded by a halo of polar residues of lesser importance for binding energy. Kinetic studies indicate that the primary role of the functional epitopes is to stabilize protein-protein interaction by decreasing the dissociation rate of the complex. It has been suggested that the initial contact between cytokine and receptor is dominated by random diffusion or 'rolling' of protein surfaces producing many unstable contacts. The complex is then stabilized when the functional epitopes of the receptor and ligand engage. *See, e.g.*, Bravo and Heath, *supra.*

III. Generation of IL-23 Specific Antibodies

[0090] Any suitable method for generating monoclonal antibodies may be used. For example, a recipient may be immunized with a linked or unlinked (e.g. naturally occurring) form of the IL-23 heterodimer, or a fragment thereof. Any suitable method of immunization can be used. Such methods can include adjuvants, other immunostimulants, repeated booster immunizations, and the use of one or more immunization routes.

[0091] Any suitable source of IL-23 can be used as the immunogen for the generation of the non-human antibody, specific for the p 19 subunit, of the compositions and methods disclosed herein. Such forms include, but are not limited whole protein, including linked and naturally occurring heterodimers, peptide(s), and epitopes, generated through recombinant, synthetic, chemical or enzymatic degradation means known in the art. In various embodiments the IL-23 immunogen may be, e.g., a human p19 polypeptide, a natural heterodimeric complex of human p19 and p40 (two disulfide-crosslinked

polypeptide chains), a fusion protein comprising human p40 and p19 sequences (*see* U.S. Patent No. 7,090,847), or chimeric IL-23 (e.g. human p19:mouse p40).

[0092] Any form of the antigen can be used to generate the antibody that is sufficient to generate a biologically active antibody. Thus, the eliciting antigen may be a single epitope, multiple epitopes, or the entire protein alone or in combination with one or more immunogenicity enhancing agents known in the art. The eliciting antigen may be an isolated full-length protein, a cell surface protein (*e.g.*, immunizing with cells transfected with at least a portion of the antigen), or a soluble protein (*e.g.*, immunizing with only the extracellular domain portion of the protein). The antigen may be produced in a genetically modified cell. The DNA encoding the antigen may genomic or non-genomic (*e.g.*, cDNA) and encodes at least a portion of the extracellular domain. As used herein, the term "portion" refers to the minimal number of amino acids or nucleic acids, as appropriate, to constitute an immunogenic epitope of the antigen of interest. Any genetic vectors suitable for transformation of the cells of interest may be employed, including but not limited to adenoviral vectors, plasmids, and non-viral vectors, such as cationic lipids.

[0093] Any suitable method can be used to elicit an antibody with the desired biologic properties to inhibit IL-23. It is desirable to prepare monoclonal antibodies (mAbs) from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, *e.g.*, Stites *et al.* (eds.) BASIC AND CLINICAL IMMUNOLOGY (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) ANTIBODIES: A LABORATORY MANUAL CSH Press; Goding (1986) MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, NY. Thus, monoclonal antibodies may be obtained by a variety of techniques familiar to researchers skilled in the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell. *See* Kohler and Milstein (1976) *Eur. J. Immunol.* 6:511-519. Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. *See, e.g.*, Doyle *et al.* (eds. 1994 and periodic supplements) CELL AND TISSUE CULTURE: LABORATORY PROCEDURES, John Wiley and Sons, New York, NY. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various

techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a antigen binding fragment thereof by screening a DNA library from human B cells according, *e.g.*, to the general protocol outlined by Huse *et al.* (1989) *Science* 246:1275-1281.

[0094] Other suitable techniques involve selection of libraries of antibodies in phage or similar vectors. *See, e.g.*, Huse *et al. supra*; and Ward *et al.* (1989) *Nature* 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, *see* Cabilly U.S. Patent No. 4,816,567; and Queen *et al.* (1989) *Proc. Nat'l Acad. Sci. USA* 86:10029-10033; or made in transgenic mice, see Mendez *et al.* (1997) *Nature Genetics* 15:146-156. *See also* Abgenix and Medarex technologies.

[0095] Antibodies or binding compositions against predetermined fragments of IL-23 can be raised by immunization of animals with conjugates of the polypeptide, fragments, peptides, or epitopes with carrier proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective IL-23. These monoclonal antibodies will usually bind with at least a K_d of about 1 μM, more usually at least about 300 nM, 30 nM, 10 nM, 3 nM, 1 nM, 300 pM, 100 pM, 30 pM or better, usually determined by ELISA. Suitable non-human antibodies may also be identified using the biologic assays described in Example 5, below.

IV. Humanization of IL-23 Specific Antibodies

[0096] Any suitable non-human antibody can be used as a source for the hypervariable region. Sources for non-human antibodies include, but are not limited to, murine, Lagomorphs (including rabbits), bovine, and primates. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which

hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance of the desired biological activity. For further details, see Jones *et al.* (1986) *Nature* 321:522-525; Reichmann *et al.* (1988) *Nature* 332:323-329; and Presta (1992) *Curr. Op. Struct. Biol.* 2:593-596.

[0097] Methods for recombinantly engineering antibodies have been described, *e.g.*, by Boss *et al.* (U.S. Pat. No. 4,816,397), Cabilly *et al.* (U.S. Pat. No. 4,816,567), Law *et al.* (European Patent Application Publication No. EP438310A1) and Winter (European Patent Application Publication No. EP239400B1).

[0098] Amino acid sequence variants of humanized anti-IL-23 antibody are prepared by introducing appropriate nucleotide changes into the humanized anti-IL-23 antibody DNA, or by peptide synthesis. Such variants include, for example, deletions from, and/or insertions into, and/or substitutions of, residues within the amino acid sequences shown for the humanized anti-IL-23 antibody (*e.g.* as in SEQ ID NOs: 1 and 2). Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the humanized anti-IL-23 antibody, such as changing the number or position of glycosylation sites.

[0099] A useful method for identification of certain residues or regions of the humanized anti-IL-23p19 antibody polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells (1989) *Science* 244: 1081-1085. Here, a residue or group of target residues are identified (*e.g.*, charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with IL-23 antigen. The amino acid residues demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be

predetermined. For example, to analyze the performance of a mutation at a given site, Ala scanning or random mutagenesis is conducted at the target codon or region and the expressed humanized anti-IL-23p19 antibody variants are screened for the desired activity.

[0100] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include humanized anti-IL-23 antibody with an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertional variants of the humanized anti-IL-23 antibody molecule include the fusion to the N- or C-terminus of humanized anti-IL-23 antibody of an enzyme or a polypeptide which increases the serum half-life of the antibody.

[0101] Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the humanized anti-IL-23p19 antibody molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable loops, but FR alterations are also contemplated.

[0102] Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

[0103] Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by

the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

[0104] Yet another type of amino acid variant is the substitution of residues to provide for greater chemical stability of the final humanized antibody. For example, an asparagine (N) residue may be changed to reduce the potential for formation of isoaspartate at any NG sequences within a rodent CDR. A similar problem may occur at a DG sequence. Reissner and Aswad (2003) *Cell. Mol. Life Sci.* 60:1281. In one embodiment, the asparagine is changed to glutamine (Q). Isoaspartate formation may debilitate or completely abrogate binding of an antibody to its target antigen. Presta (2005) *J. Allergy Clin. Immunol.* 116:731 at 734. In addition, methionine residues in rodent CDRs may be changed to reduce the possibility that the methionine sulfur would oxidize, which could reduce antigen binding affinity and also contribute to molecular heterogeneity in the final antibody preparation. *Id.* In one embodiment, the methionine is changed to alanine (A). Antibodies with such substitutions are subsequently screened to ensure that the substitutions do not decrease IL-23p19 binding affinity to unacceptable levels.

[0105] Nucleic acid molecules encoding amino acid sequence variants of humanized IL-23 specific antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of humanized anti-IL-23p19 antibody.

[0106] Ordinarily, amino acid sequence variants of the humanized anti-IL-23 antibody will have an amino acid sequence having at least 75% amino acid sequence identity with the original humanized antibody amino acid sequences of either the heavy or the light chain more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95, 98, or 99%. Identity or homology with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the humanized anti-IL-23 residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence shall be construed as affecting sequence identity or homology.

[0107] The humanized antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE. Preferably, the antibody is an IgG antibody. Any isotype of IgG can be used, including IgG_1, IgG_2, IgG_3, and IgG_4. Variants of the IgG isotypes are also contemplated. The humanized antibody may comprise sequences from more than one class or isotype. Optimization of the necessary constant domain sequences to generate the desired biologic activity is readily achieved by screening the antibodies in the biological assays described below.

[0108] Likewise, either class of light chain can be used in the compositions and methods herein. Specifically, kappa, lambda, or variants thereof are useful in the present compositions and methods.

[0109] Any suitable portion of the CDR sequences from the non-human antibody can be used. The CDR sequences can be mutagenized by substitution, insertion or deletion of at least one residue such that the CDR sequence is distinct from the human and non-human antibody sequence employed. It is contemplated that such mutations would be minimal. Typically, at least 75% of the humanized antibody residues will correspond to those of the non-human CDR residues, more often 90%, and most preferably greater than 95, 98, or 99%.

[0110] Any suitable portion of the FR sequences from the human antibody can be used. The FR sequences can be mutagenized by substitution, insertion or deletion of at least one residue such that the FR sequence is distinct from the human and non-human antibody sequence employed. It is contemplated that such mutations would be minimal. Typically, at least 75% of the humanized antibody residues will correspond to those of the human FR residues, more often 90%, and most preferably greater than 95%.

[0111] CDR and FR residues are determined according to the standard sequence definition of Kabat. Kabat *et al.* (1987) Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda Md. SEQ ID NOs: 5 – 16, 31 – 47 and 93 – 105 show the heavy chain variable domain sequences of various mouse anti-human IL-23p19 antibodies, and SEQ ID NOs: 17 – 28, 48 – 64 and 106 – 118 depict the light chain variable domain sequences. SEQ ID NOs: 65 – 67 are consensus sequences for heavy chain CDRs (CDRH1, CDRH2 and CDRH3), and are comprised of the most common amino acid residue at each position in the heavy chain CDRs for the family of antibodies consisting of 7G10, 6H12, 13F11, 13B5, 7E2, 13G1, 11C10, 1E10, 30F11, 5B12, 6H4, 9C9, 11B10,

33D2, 20A9, 22E9, 29D5, 21A10, 2G12, 15G2, 18E1 and 2C6. FIGS. 1A-1C provide a sequence lineup of heavy chains of various antibodies of the present invention. This heavy chain variable domain consensus sequence is referred to as conH (SEQ ID NO: 119).

[0112] As illustrated in FIGS. 1A-1C, the consensus heavy chain variable domain is closely related to mouse germline sequences IGHV1-14 (SEQ ID NO: 120) in conjunction with IGHD-Q52 (NWD, which is not included in the Sequence Listing because it comprises fewer than four amino acid residues) and either IGHJ2 (SEQ ID NO: 121) or IGHJ3 (SEQ ID NO: 122). The VH subgroups are listed in M.-P. Lefranc (2001) "Nomenclature of the Human Immunoglobulin Heavy (IGH) Genes", *Experimental and Clinical Immunogenetics* 18:100-116. Sequences for these mouse germlines are also available at GenBank Accession Nos. AC090843 (muIGHV1-14), L32868 (nt 2948-2956) (muIGHD-Q52), V00770 (nt 383-430) (muIGHJ2) and V00770 (nt 766-813) (muIGHJ3). In one embodiment of the present invention, the anti-IL-23p19 antibody heavy chain variable region, and particularly CDRH1 and/or CDRH2, comprises a sequence that is closely related to these mouse germline sequences, e.g. mouse germline sequence IGHV1-14. In some embodiments the heavy chain variable region, CDRH1 or CDRH2 exhibit 80%, 85%, 90%, 95%, 98%, 99% or greater homology with mouse germline sequence IGHV1-14. In other embodiments the heavy chain variable region, CDRH1 or CDRH2 exhibit 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20 or more amino acid changes relative to mouse germline sequence IGHV1-14. In yet further embodiments such anti-IL-23p19 antibody heavy chains, or CDRH1 and/or CDRH2, may further comprise one or more conservative amino acid substitutions (as defined at Table 1) relative to mouse germline sequence IGHV1-14. In humanized antibody embodiments it is the CDRs, rather than the framework sequences, that are homologous to the recited mouse germlines.

[0113] As shown in FIGS. 2A-2C, the light chain CDRs of the antibodies of the present invention disclosed herein are grouped into three subfamilies, referred to as (a), (b) and (c). Light chain subfamily (a) consists of antibodies 7G10, 6H12, 33B12, 13F11, 13B5, 13G1, 11C10, 7E2, 30F11, 34E4, 6H4, 33D2, 2C6, 2G12, 1D6, 18E1, 15G2, 17G8, 20A4, 20H7, 3C4 and 8E9. Light chain subfamily (b) consists of antibodies 1E10, 20A9, 22E9, 29D5, 5B12, 9C9 and 11B10. Light chain subfamily (c) consists of antibodies 10G8, 19E9, 10H11, 39G2, 35F12, 49A10, 34F9 and 7D7. These light chain subfamilies were used to derive consensus CDR sequences of CDRL1(a), CDRL1(b) and CDRL1(c) (SEQ ID

NOs: 68 – 70) and corresponding consensus sequences CDRL2 (SEQ ID NOs: 71 – 73) and CDRL3 (SEQ ID NOs: 74 – 76) for each subfamily. Consensus sequences for light chain CDRs are comprised of the most common amino acid residue at each position in the light chain CDRs for each subfamily of antibodies. The light chain variable domain consensus sequences for families (a), (b) and (c) are referred to as conLA (SEQ ID NO: 123), conLB (SEQ ID NO: 125) and conLC (SEQ ID NO: 127) in FIGS. 2A-2C.

[0114] As illustrated in FIGS. 2A-2C, the consensus light chain variable domain for family (a) (conLA) is closely related to mouse germline sequence IGKV5-39 (SEQ ID NO: 124); the consensus light chain variable domain for family (b) (conLB) is closely related to mouse germline sequence IGKV8-30 (SEQ ID NO: 126); and the consensus light chain variable domain for family (c) (conLC) is closely related to mouse germline sequence IGVK3-12 (SEQ ID NO: 128). Sequences for these mouse germlines are also available at GenBank Accession Nos. AJ235964 (nt 403-689) (IGKV5-39), AJ235948 (nt 441-745) (IGKV8-30), and K02159 (nt 362-660) (IGVK3-12). In one embodiment of the present invention, the anti-IL-23p19 antibody light chain variable region, and particularly the light chain CDRs, comprises a sequence that is closely related to one or more of these three mouse germline sequences (IGKV5-39, IGKV8-30, IGVK3-12). In some embodiments the light chain variable region, or any of the light chain CDRs, exhibit 80%, 85%, 90%, 95%, 98%, 99% or greater homology with one or more of the three mouse germline sequences. In other embodiments the heavy chain variable region, or any of the light chain CDRs, exhibit 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20 or more amino acid changes relative to one or more of the three mouse germline sequences. In yet further embodiments such anti-IL-23p19 antibody light chains, and particularly the light chain CDRs, may further comprise one or more conservative amino acid substitutions (as defined at Table 1) relative to one or more of the three mouse germline sequences. In humanized antibody embodiments it is the CDRs, rather than the framework sequences, that are homologous to the recited mouse germlines.

[0115] Tables 2 and 3 define various domains of humanized anti-IL-23p19 antibodies 6H12, 7G10, 10H11, 22E9 and 17G8 (with two variant heavy chain variable domains), as well as and the light and heavy chain variable domains of several murine antibodies of the present invention. Residues 1-19 of SEQ ID NOs: 1 – 4 represent signal sequences for heavy and light strands of hum6H12 and hum7G10. Light chain constant domains of hum6H12 and hum7G10 are at residues 130-233 of SEQ ID NOs: 2 and 4,

respectively. Heavy chain constant domains of hum6H12 and hum7G10 are at residues 135-464 of SEQ ID NOs: 1 and 3, respectively, with CH1 at residues 135-242, CH2+hinge at residues 243-357 and CH3 at residues 358-464. These constant domains may be combined with variable domains from the other murine antibodies disclosed herein to create chimeric antibodies, or with humanized variable domains to create humanized antibodies. All other antibodies are presented as light and heavy chain variable regions (V_L and V_H), and thus lack signal sequences and constant domains.

Table 2

Light Chain Sequences and Domains

ANTIBODY CLONE	SEQ ID NO:	V_L RESIDUES	LIGHT CHAIN CDR RESIDUES		
			CDRL1	CDRL2	CDRL3
hum6H12	2	20-129	43-53	69-75	108-116
hum7G10	4	20-129	43-53	69-75	108-116
hum10H11	90	1-114	24-38	54-60	93-101
hum22E9	92	1-116	24-40	56-62	95-103
hum17G8	131	1-108	24-34	50-56	89-97
m6H12	17	1-108	24-34	50-56	89-97
m7G10	18	1-108	24-34	50-56	89-97
m13F11	19	1-108	24-34	50-56	89-97
m13B5	20	1-108	24-34	50-56	89-97
m21A10	21	1-108	24-34	50-56	89-97
m33B12	22	1-108	24-34	50-56	89-97
m39G2	23	1-112	24-38	54-60	93-101
m35F12	24	1-112	24-38	54-60	93-101
m49A10	25	1-112	24-38	54-60	93-101
m34F9	26	1-112	24-38	54-60	93-101
m7D7	27	1-112	24-38	54-60	93-101
m3D7	28	1-108	24-34	50-56	89-97
m13G1	48	1-108	24-34	50-56	89-97
m11C10	49	1-108	24-34	50-56	89-97
m7E2	50	1-108	24-34	50-56	89-97
m30F11	51	1-108	24-34	50-56	89-97

m34E4	52	1-108	24-34	50-56	89-97
m6H4	53	1-108	24-34	50-56	89-97
m33D2	54	1-108	24-34	50-56	89-97
m1E10	55	1-114	24-40	56-62	95-103
m20A9	56	1-114	24-40	56-62	95-103
m22E9	57	1-114	24-40	56-62	95-103
m29D5	58	1-114	24-40	56-62	95-103
m5B12	59	1-114	24-40	56-62	95-103
m9C9	60	1-114	24-40	56-62	95-103
m11B10	61	1-114	24-40	56-62	95-103
m10G8	62	1-112	24-38	54-60	93-101
m19E9	63	1-112	24-38	54-60	93-101
m10H11	64	1-112	24-38	54-60	93-101
m2G12	106	1-108	24-34	50-56	89-97
m15G2	107	1-108	24-34	50-56	89-97
m18E1	108	1-108	24-34	50-56	89-97
m2C6	109	1-108	24-34	50-56	89-97
m8E9	110	1-108	24-34	50-56	89-97
m1D6	111	1-108	24-34	50-56	89-97
m17G8	112	1-108	24-34	50-56	89-97
m20A4	113	1-108	24-34	50-56	89-97
m20H7	114	1-108	24-34	50-56	89-97
m3C4	115	1-108	24-34	50-56	89-97
m16F7	116	1-108	24-34	50-56	89-97
m14A3	117	1-112	24-38	54-60	93-101
m12C11	118	1-112	24-38	54-60	93-101

Table 3

Heavy Chain Sequences and Domains

ANTIBODY CLONE	SEQ ID NO:	V_H RESIDUES	HEAVY CHAIN CDR RESIDUES		
			CDRH1	CDRH2	CDRH3
hum6H12	1	20-134	45-54	69-85	118-123
hum7G10	3	20-134	45-54	69-85	118-123

hum10H11	89	1-118	26-35	50-66	99-107
hum22E9	91	1-115	26-35	50-66	99-104
hum17G8-A	129	1-115	26-35	50-66	99-104
hum17G8-B	130	1-115	26-35	50-66	99-104
m6H12	5	1-115	26-35	50-66	99-104
m7G10	6	1-115	26-35	50-66	99-104
m13F11	7	1-115	26-35	50-66	99-104
m13B5	8	1-116	26-35	50-66	99-105
m21A10	9	1-115	26-35	50-66	99-104
m33B12	10	1-115	26-35	50-66	99-104
m39G2	11	1-118	26-35	50-66	99-107
m35F12	12	1-118	26-35	50-66	99-107
m49A10	13	1-119	26-35	50-66	99-108
m3D7	14	1-122	26-35	50-66	99-111
m34F9	15	1-124	26-35	50-66	99-113
m7D7	16	1-124	26-35	50-66	99-113
m13G1	31	1-115	26-35	50-66	99-104
m11C10	32	1-115	26-35	50-66	99-104
m7E2	33	1-115	26-35	50-66	99-104
m30F11	34	1-115	26-35	50-66	99-104
m34E4	35	1-115	26-35	50-66	99-104
m6H4	36	1-115	26-35	50-66	99-104
m33D2	37	1-115	26-35	50-66	99-104
m1E10	38	1-115	26-35	50-66	99-104
m20A9	39	1-115	26-35	50-66	99-104
m22E9	40	1-115	26-35	50-66	99-104
m29D5	41	1-115	26-35	50-66	99-104
m5B12	42	1-115	26-35	50-66	99-104
m9C9	43	1-115	26-35	50-66	99-104
m11B10	44	1-115	26-35	50-66	99-104
m10G8	45	1-118	26-35	50-66	99-107
m19E9	46	1-118	26-35	50-66	99-107
m10H11	47	1-118	26-35	50-66	99-107
m2G12	93	1-115	26-35	50-66	99-104
m15G2	94	1-115	26-35	50-66	99-104

m18E1	95	1-115	26-35	50-66	99-104
m2C6	96	1-115	26-35	50-66	99-104
m8E9	97	1-115	26-35	50-66	99-104
m1D6	98	1-115	26-35	50-66	99-104
m17G8	99	1-115	26-35	50-66	99-104
m20A4	100	1-115	26-35	50-66	99-104
m20H7	101	1-115	26-35	50-66	99-104
m3C4	102	1-115	26-35	50-66	99-104
m16F7	103	1-119	26-35	50-66	99-108
m14A3	104	1-122	26-35	50-66	99-111
m12C11	105	1-122	26-35	50-66	99-111

[0116] In one embodiment, the antibodies of the present invention or antigen binding fragments thereof comprise CDRs comprising one of several variable amino acids at certain positions. In one embodiment antibodies of the present invention, or antigen binding fragments thereof, comprise the "CDR Variable" domains listed at SEQ ID NOs: 77 – 88. These "CDR Variable" sequences include the consensus sequence of each family of related antibodies as well as variable positions encompassing all observed sequence variants within that family. Such sequence variants are displayed in FIGS. 1A – 1C and 2A – 2C.

[0117] In another embodiment, the variable amino acids in potential CDRs are selected from those amino acids appearing two or more times in the families reported herein. These antibodies are a subset of the "CDR Variable" antibodies described above in which amino acids that appear only once at a given position in a CDR in a given family of sequences are not included in the pool of potential CDRs. These "single occurrence" amino acid substitutions are readily determined, and thus excluded from the "CDR Variable" sequences, by simple inspection of FIGS. 1A – 1C and 2A – 2C. This narrowed range of potential CDR sequences is referred to herein as a "multiple occurrence variable CDR." This nomenclature is used herein for convenience in referring to this subset of the "CDR Variable" sequences.

[0118] In yet another embodiment, potential CDRs are not limited to the "CDR Variable" sequences described above, but also include conservatively modified variants of any observed amino acid, as determined using the data of Table 1.

[0119] In a further embodiment, potential CDRs include variants of any single sequence CDR disclosed herein, including consensus sequences SEQ ID NOs: 65 – 76, in which the variant comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more conservative amino acid substitutions relative to the disclosed sequence, as determined using the data of Table 1.

[0120] Also contemplated are chimeric antibodies. As noted above, typical chimeric antibodies comprise a portion of the heavy and/or light chain identical with, or homologous to, corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. *See* U.S. Pat. No. 4,816,567; and Morrison *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81: 6851-6855.

[0121] Bispecific antibodies are also useful in the present methods and compositions. As used herein, the term "bispecific antibody" refers to an antibody, typically a monoclonal antibody, having binding specificities for at least two different antigenic epitopes, e.g., IL-23p19 and IL-17. In one embodiment, the epitopes are from the same antigen. In another embodiment, the epitopes are from two different antigens. Methods for making bispecific antibodies are known in the art. For example, bispecific antibodies can be produced recombinantly using the co-expression of two immunoglobulin heavy chain/light chain pairs. *See, e.g.,* Milstein *et al.* (1983) *Nature* 305: 537-39. Alternatively, bispecific antibodies can be prepared using chemical linkage. *See, e.g.,* Brennan *et al.* (1985) *Science* 229:81. Bispecific antibodies include bispecific antibody fragments. *See, e.g.,* Holliger *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6444-48, Gruber *et al.* (1994) *J. Immunol.* 152:5368.

[0122] In yet other embodiments, different constant domains may be appended to the humanized V_L and V_H regions provided herein. For example, if a particular intended use of an antibody (or fragment) of the present invention were to call for altered effector functions, a heavy chain constant domain other than IgG1 may be used. Although IgG1 antibodies provide for long half-life and for effector functions, such as complement activation and antibody-dependent cellular cytotoxicity, such activities may not be desirable for all uses of the antibody. In such instances an IgG4 constant domain, for example, may be used.

V. Biological Activity of Humanized Anti-IL-23

[0123] Antibodies having the characteristics identified herein as being desirable in a humanized anti-IL-23 antibody can be screened for inhibitory biologic activity *in vitro* or suitable binding affinity. To screen for antibodies that bind to the epitope on human IL-23 (i.e. the p19 subunit) bound by an antibody of interest (*e.g.*, those that block binding of the cytokine to its receptor), a routine cross-blocking assay such as that described in ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Antibodies that bind to the same epitope are likely to cross-block in such assays, but not all cross-blocking antibodies will necessarily bind at precisely the same epitope since cross-blocking may result from steric hindrance of antibody binding by antibodies bind at nearby, or even non-overlapping, epitopes.

[0124] Alternatively, epitope mapping, *e.g.*, as described in Champe *et al.* (1995) *J. Biol. Chem.* 270:1388-1394, can be performed to determine whether the antibody binds an epitope of interest. "Alanine scanning mutagenesis," as described by Cunningham and Wells (1989) *Science* 244: 1081-1085, or some other form of point mutagenesis of amino acid residues in human IL-23 may also be used to determine the functional epitope for an anti-IL-23 antibody of the present invention. Mutagenesis studies, however, may also reveal amino acid residues that are crucial to the overall three-dimensional structure of IL-23 but that are not directly involved in antibody-antigen contacts, and thus other methods may be necessary to confirm a functional epitope determined using this method.

[0125] The epitope bound by a specific antibody may also be determined by assessing binding of the antibody to peptides comprising fragments of human IL-23p19 (SEQ ID NO: 39). A series of overlapping peptides encompassing the sequence of IL-23p19 may be synthesized and screened for binding, e.g. in a direct ELISA, a competitive ELISA (where the peptide is assessed for its ability to prevent binding of an antibody to IL-23p19 bound to a well of a microtiter plate), or on a chip. Such peptide screening methods may not be capable of detecting some discontinuous functional epitopes, i.e. functional epitopes that involve amino acid residues that are not contiguous along the primary sequence of the IL-23p19 polypeptide chain.

[0126] The epitope bound by antibodies of the present invention may also be determined by structural methods, such as X-ray crystal structure determination (*e.g.*,

WO2005/044853), molecular modeling and nuclear magnetic resonance (NMR) spectroscopy, including NMR determination of the H–D exchange rates of labile amide hydrogens in IL-23 when free and when bound in a complex with an antibody of interest (Zinn-Justin *et al.*(1992) *Biochemistry* 31:11335–11347; Zinn-Justin *et al.* (1993) *Biochemistry* 32:6884–6891).

[0127] With regard to X-ray crystallography, crystallization may be accomplished using any of the known methods in the art (*e.g.* Giege *et al.* (1994) *Acta Crystallogr.* D50:339-350; McPherson (1990) *Eur. J. Biochem.* 189:1-23), including microbatch (*e.g.* Chayen (1997) *Structure* 5:1269-1274), hanging-drop vapor diffusion (*e.g.* McPherson (1976) *J. Biol. Chem.* 251:6300-6303), seeding and dialysis. It is desirable to use a protein preparation having a concentration of at least about 1 mg/mL and preferably about 10 mg/mL to about 20 mg/mL. Crystallization may be best achieved in a precipitant solution containing polyethylene glycol 1000-20,000 (PEG; average molecular weight ranging from about 1000 to about 20,000 Da), preferably about 5000 to about 7000 Da, more preferably about 6000 Da, with concentrations ranging from about 10% to about 30% (w/v). It may also be desirable to include a protein stabilizing agent, e.g. glycerol at a concentration ranging from about 0.5% to about 20%. A suitable salt, such as sodium chloride, lithium chloride or sodium citrate may also be desirable in the precipitant solution, preferably in a concentration ranging from about 1 mM to about 1000 mM. The precipitant is preferably buffered to a pH of from about 4.0 to about 10.0, often from about 7.0 to 8.5, e.g. pH 8.0. Specific buffers useful in the precipitant solution may vary and are well-known in the art. Scopes, Protein Purification: Principles and Practice, Third ed., (1994) Springer-Verlag, New York. Examples of useful buffers include, but are not limited to, HEPES, Tris, MES and acetate. Crystals may be grow at a wide range of temperatures, including 2°C, 4°C, 8°C and 26°C.

[0128] Antibody:antigen crystals may be studied using well-known X-ray diffraction techniques and may be refined using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; *see e.g.* Blundell & Johnson (1985) *Meth. Enzymol.* 114 & 115, H. W. Wyckoff *et al.* eds., Academic Press; U.S. Patent Application Publication No. 2004/0014194), and BUSTER (Bricogne (1993) *Acta Cryst.* D49:37-60; Bricogne (1997) *Meth. Enzymol.* 276A:361-423, Carter & Sweet, eds.; Roversi *et al.* (2000) *Acta Cryst.* D56:1313-1323).

[0129] Additional antibodies binding to the same epitope as an antibody of the present invention may be obtained, for example, by screening of antibodies raised against IL-23 for binding to the epitope, or by immunization of an animal with a peptide comprising a fragment of human IL-23 comprising the epitope sequence. Antibodies that bind to the same functional epitope might be expected to exhibit similar biological activities, such as blocking receptor binding, and such activities can be confirmed by functional assays of the antibodies.

[0130] Antibody affinities (*e.g.* for human IL-23) may be determined using standard analysis. Preferred humanized antibodies are those which bind human IL-23p19 with a K_d value of no more than about $1x10^{-7}$; preferably no more than about $1x10^{-8}$; more preferably no more than about $1x10^{-9}$; and most preferably no more than about $1x10^{-10}$ or even $1x10^{-11}$ M.

[0131] The antibodies and fragments thereof useful in the present compositions and methods are biologically active antibodies and fragments. As used herein, the term "biologically active" refers to an antibody or antibody fragment that is capable of binding the desired the antigenic epitope and directly or indirectly exerting a biologic effect. Typically, these effects result from the failure of IL-23 to bind its receptor. As used herein, the term "specific" refers to the selective binding of the antibody to the target antigen epitope. Antibodies can be tested for specificity of binding by comparing binding to IL-23 to binding to irrelevant antigen or antigen mixture under a given set of conditions. If the antibody binds to IL-23 at least 10, and preferably 50 times more than to irrelevant antigen or antigen mixture then it is considered to be specific. An antibody that binds to IL-12 is not an IL-23-specific antibody. An antibody that "specifically binds" to IL-23p19 does not bind to proteins that do not comprise the IL-23p19-derived sequences, i.e. "specificity" as used herein relates to IL-23p19 specificity, and not any other sequences that may be present in the protein in question. For example, as used herein, an antibody that "specifically binds" to IL-23p19 will typically bind to FLAG®-hIL-23p19, which is a fusion protein comprising IL-23p19 and a FLAG® peptide tag, but it does not bind to the FLAG® peptide tag alone or when it is fused to a protein other than IL-23p19.

[0132] IL-23-specific binding compounds of the present invention, such as inhibitory IL-23p19 specific antibodies, can inhibit its biological activity in any manner, including but not limited to production of IL-1β and TNF by peritoneal macrophages and

IL-17 by T_H17 T cells. *See* Langrish *et al.* (2004) *Immunol. Rev.* 202:96-105. Anti-IL-23p19 antibodies will also be able to inhibit the gene expression of IL-17A, IL-17F, CCL7, CCL17, CCL20, CCL22, CCR1, and GM-CSF. *See* Langrish *et al.* (2005) *J. Exp. Med.* 201:233-240. IL-23-specific binding compounds of the present invention, such as anti IL-23p19 antibodies, will also block the ability of IL-23 to enhance proliferation or survival of T_H17 cells. Cua and Kastelein (2006) *Nat. Immunol.* 7:557-559. The inhibitory activity of engineered anti-IL-23p19 will be useful in the treatment of inflammatory, autoimmune, and proliferative disorders. Examples of such disorders are described in PCT patent application publications WO 04/081190; WO 04/071517; WO 00/53631; and WO 01/18051.

VI. Pharmaceutical Compositions

[0133] To prepare pharmaceutical or sterile compositions including IL-23p19 antibody, the cytokine analogue or mutein, antibody thereto, or nucleic acid thereof, is admixed with a pharmaceutically acceptable carrier or excipient. *See, e.g., Remington's Pharmaceutical Sciences* and *U.S. Pharmacopeia: National Formulary*, Mack Publishing Company, Easton, PA (1984).

[0134] Formulations of therapeutic and diagnostic agents may be prepared by mixing with physiologically acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions or suspensions. *See, e.g.*, Hardman *et al.* (2001) *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, McGraw-Hill, New York, NY; Gennaro (2000) *Remington: The Science and Practice of Pharmacy*, Lippincott, Williams, and Wilkins, New York, NY; Avis *et al.* (eds.) (1993) *Pharmaceutical Dosage Forms: Parenteral Medications*, Marcel Dekker, NY; Lieberman, *et al.* (eds.) (1990) *Pharmaceutical Dosage Forms: Tablets*, Marcel Dekker, NY; Lieberman *et al.* (eds.) (1990) *Pharmaceutical Dosage Forms: Disperse Systems*, Marcel Dekker, NY; Weiner and Kotkoskie (2000) *Excipient Toxicity and Safety*, Marcel Dekker, Inc., New York, NY.

[0135] Toxicity and therapeutic efficacy of the antibody compositions, administered alone or in combination with an immunosuppressive agent, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.,* for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio of LD_{50} to ED_{50}. Antibodies

exhibiting high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.

[0136] The mode of administration is not particularly important. Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, intradermal, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of antibody used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral, intraarterial or intravenous injection.

[0137] Alternately, one may administer the antibody in a local rather than systemic manner, for example, via injection of the antibody directly into an arthritic joint or pathogen-induced lesion characterized by immunopathology, often in a depot or sustained release formulation. Furthermore, one may administer the antibody in a targeted drug delivery system, for example, in a liposome coated with a tissue-specific antibody, targeting, for example, arthritic joint or pathogen-induced lesion characterized by immunopathology. The liposomes will be targeted to and taken up selectively by the afflicted tissue.

[0138] Selecting an administration regimen for a therapeutic depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells in the biological matrix. Preferably, an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of biologic delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate doses of antibodies, cytokines, and small molecules are available. *See, e.g.*, Wawrzynczak (1996) *Antibody Therapy*, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.) (1991) *Monoclonal Antibodies, Cytokines and Arthritis*, Marcel Dekker, New York, NY; Bach (ed.) (1993) *Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases*, Marcel Dekker, New York, NY;

Baert *et al.* (2003) *New Engl. J. Med.* 348:601-608; Milgrom *et al.* (1999) *New Engl. J. Med.* 341:1966-1973; Slamon *et al.* (2001) *New Engl. J. Med.* 344:783-792; Beniaminovitz *et al.* (2000) *New Engl. J. Med.* 342:613-619; Ghosh *et al.* (2003) *New Engl. J. Med.* 348:24-32; Lipsky *et al.* (2000) *New Engl. J. Med.* 343:1594-1602.

[0139] Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects. Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced. Preferably, a biologic that will be used is substantially derived from the same species as the animal targeted for treatment (e.g. a humanized antibody for treatment of human subjects), thereby minimizing any immune response to the reagent.

[0140] Antibodies, antibody fragments, and cytokines can be provided by continuous infusion, or by doses at intervals of, e.g., one day, 1-7 times per week, one week, two weeks, monthly, bimonthly, etc. Doses may be provided intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscular, intracerebrally, intraspinally, or by inhalation. A preferred dose protocol is one involving the maximal dose or dose frequency that avoids significant undesirable side effects. A total weekly dose is generally at least 0.05 μg/kg, 0.2 μg/kg, 0.5 μg/kg, 1 μg/kg, 10 μg/kg, 100 μg/kg, 0.2 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 10 mg/kg, 25 mg/kg, 50 mg/kg body weight or more. *See, e.g.*, Yang *et al.* (2003) *New Engl. J. Med.* 349:427-434; Herold *et al.* (2002) *New Engl. J. Med.* 346:1692-1698; Liu *et al.* (1999) *J. Neurol. Neurosurg. Psych.* 67:451-456; Portielji *et al.* (20003) *Cancer Immunol. Immunother.* 52:133-144. The desired dose of a small molecule therapeutic, e.g., a peptide mimetic, natural product, or organic chemical, is about the same as for an antibody or polypeptide, on a moles/kg basis.

[0141] As used herein, “inhibit” or “treat” or “treatment” includes a postponement of development of the symptoms associated with autoimmune disease or pathogen-induced immunopathology and/or a reduction in the severity of such symptoms that will or are expected to develop. The terms further include ameliorating existing uncontrolled or unwanted autoimmune-related or pathogen-induced immunopathology symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of

such symptoms. Thus, the terms denote that a beneficial result has been conferred on a vertebrate subject with an autoimmune or pathogen-induced immunopathology disease or symptom, or with the potential to develop such a disease or symptom.

[0142] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount of an IL-23p19 specific binding compound, e.g. and antibody, that when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject is effective to prevent or ameliorate the autoimmune disease or pathogen-induced immunopathology associated disease or condition or the progression of the disease. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms, *e.g.,* treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. An effective amount of therapeutic will decrease the symptoms typically by at least 10%; usually by at least 20%; preferably at least about 30%; more preferably at least 40%, and most preferably by at least 50%.

[0143] Methods for co-administration or treatment with a second therapeutic agent, e.g., a cytokine, antibody, steroid, chemotherapeutic agent, antibiotic, or radiation, are well known in the art, see, e.g., Hardman *et al.* (eds.) (2001) *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 10th ed., McGraw-Hill, New York, NY; Poole and Peterson (eds.) (2001) *Pharmacotherapeutics for Advanced Practice: A Practical Approach*, Lippincott, Williams & Wilkins, Phila., PA; Chabner and Longo (eds.) (2001) *Cancer Chemotherapy and Biotherapy*, Lippincott, Williams & Wilkins, Phila., PA. The pharmaceutical composition of the invention may also contain other immunosuppressive or immunomodulating agents. Any suitable immunosuppressive agent can be employed, including but not limited to anti-inflammatory agents, corticosteroids, cyclosporine, tacrolimus (*i.e.*, FK-506), sirolimus, interferons, soluble cytokine receptors (*e.g.*, sTNRF and sIL-1R), agents that neutralize cytokine activity (*e.g.*, inflixmab, etanercept), mycophenolate mofetil, 15-deoxyspergualin, thalidomide, glatiramer, azathioprine, leflunomide, cyclophosphamide, methotrexate, and the like. The pharmaceutical

composition can also be employed with other therapeutic modalities such as phototherapy and radiation.

[0144] Typical veterinary, experimental, or research subjects include monkeys, dogs, cats, rats, mice, rabbits, guinea pigs, horses, and humans.

VII. Antibody Production

[0145] In one embodiment, for recombinant production of the antibodies of the present invention, the nucleic acids encoding the two chains are isolated and inserted into one or more replicable vectors for further cloning (amplification of the DNA) or for expression. DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. In one embodiment, both the light and heavy chains of the humanized anti-IL-23p19 antibody of the present invention are expressed from the same vector, e.g. a plasmid or an adenoviral vector.

[0146] Antibodies of the present invention may be produced by any method known in the art. In one embodiment, antibodies are expressed in mammalian or insect cells in culture, such as chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) 293 cells, mouse myeloma NSO cells, baby hamster kidney (BHK) cells, *Spodoptera frugiperda* ovarian (Sf9) cells. In one embodiment, antibodies secreted from CHO cells are recovered and purified by standard chromatographic methods, such as protein A, cation exchange, anion exchange, hydrophobic interaction, and hydroxyapatite chromatography. Resulting antibodies are concentrated and stored in 20 mM sodium acetate, pH 5.5.

[0147] In another embodiment, the antibodies of the present invention are produced in yeast according to the methods described in WO2005/040395. Briefly, vectors encoding the individual light or heavy chains of an antibody of interest are introduced into different yeast haploid cells, e.g. different mating types of the yeast *Pichia pastoris*, which yeast haploid cells are optionally complementary auxotrophs. The transformed haploid yeast cells can then be mated or fused to give a diploid yeast cell capable of producing both the heavy

and the light chains. The diploid strain is then able to secret the fully assembled and biologically active antibody. The relative expression levels of the two chains can be optimized, for example, by using vectors with different copy number, using transcriptional promoters of different strengths, or inducing expression from inducible promoters driving transcription of the genes encoding one or both chains.

[0148] In one embodiment, the respective heavy and light chains of a plurality of different anti-IL-23p19 antibodies (the "original" antibodies) are introduced into yeast haploid cells to create a library of haploid yeast strains of one mating type expressing a plurality of light chains, and a library of haploid yeast strains of a different mating type expressing a plurality of heavy chains. These libraries of haploid strains can be mated (or fused as spheroplasts) to produce a series of diploid yeast cells expressing a combinatorial library of antibodies comprised of the various possible permutations of light and heavy chains. The combinatorial library of antibodies can then be screened to determine whether any of the antibodies has properties that are superior (e.g. higher affinity for IL-23) to those of the original antibodies. *See. e.g.*, WO2005/040395.

[0149] In another embodiment, antibodies of the present invention are human domain antibodies in which portions of an antibody variable domain are linked in a polypeptide of molecular weight approximately 13 kDa. See, e.g., U.S. Pat. Publication No. 2004/0110941. Such single domain, low molecular weight agents provide numerous advantages in terms of ease of synthesis, stability, and route of administration.

VIII. Uses

[0150] The present invention provides methods for using engineered anti-IL-23 antibodies and fragments thereof for the treatment and diagnosis of inflammatory disorders and conditions, e.g., of the central nervous system, peripheral nervous system, and gastrointestinal tract, as well as autoimmune and proliferative disorders.

[0151] Methods are provided for the treatment of, e.g., multiple sclerosis (MS), including relapsing-remitting MS and primary progressive MS, Alzheimer's disease, amyotrophic lateral sclerosis (a.k.a. ALS; Lou Gehrig's disease), ischemic brain injury, prion diseases, and HIV-associated dementia. Also provided are methods for treating neuropathic pain, posttraumatic neuropathies, Guillain-Barre syndrome (GBS), peripheral polyneuropathy, and nerve regeneration.

[0152] Provided are methods for treating or ameliorating one or more of the following features, symptoms, aspects, manifestations, or signs of multiple sclerosis, or other inflammatory disorder or condition of the nervous system: brain lesions, myelin lesions, demyelination, demyelinated plaques, visual disturbance, loss of balance or coordination, spasticity, sensory disturbances, incontinence, pain, weakness, fatigue, paralysis, cognitive impairment, bradyphrenia, diplopia, optic neuritis, paresthesia, gait ataxia, fatigue, Uhtoff's symptom, neuralgia, aphasia, apraxia, seizures, visual-field loss, dementia, extrapyramidal phenomena, depression, sense of well-being, or other emotional symptoms, chronic progressive myelopathy, and a symptom detected by magnetic resonance imaging (MRI), including gadolinium-enhancing lesions, evoked potential recordings, or examination of cerebrospinal fluid. *See, e.g.*, Kenealy *et al.* (2003) *J. Neuroimmunol.* 143:7-12; Noseworthy *et al.* (2000) *New Engl. J. Med.* 343:938-952; Miller *et al.* (2003) *New Engl. J. Med.* 348:15-23; Chang *et al.* (2002) *New Engl. J. Med.* 346:165-173; Bruck and Stadelmann (2003) *Neurol. Sci.* 24 Suppl.5:S265-S267.

[0153] Moreover, the present invention provides methods for treating and diagnosing inflammatory bowel disorders, e.g., Crohn's disease, ulcerative colitis, celiac disease, and irritable bowel syndrome. Provided are methods for treating or ameliorating one or more of the following symptoms, aspects, manifestations, or signs of an inflammatory bowel disorder: malabsorption of food, altered bowel motility, infection, fever, abdominal pain, diarrhea, rectal bleeding, weight loss, signs of malnutrition, perianal disease, abdominal mass, and growth failure, as well as intestinal complications such as stricture, fistulas, toxic megacolon, perforation, and cancer, and including endoscopic findings, such as, friability, aphthous and linear ulcers, cobblestone appearance, pseudopolyps, and rectal involvement and, in addition, anti-yeast antibodies. *See, e.g.*, Podolsky, *supra*; Hanauer, *supra*; Horwitz and Fisher, *supra*.

[0154] Also contemplated is treatment of inflammatory disorders such as psoriasis, atopic dermatitis, arthritis, including rheumatoid arthritis, osteoarthritis, and psoriatic arthritis, autoimmune disorders, such as systemic lupus erythematosus and type I diabetes, and proliferative disorders such as cancer. *See, e.g.*, PCT patent applications WO 04/081190; WO 04/071517; WO 00/53631; and WO 01/18051.

[0155] The IL-23p19 binding compounds of the present invention can also be used in combination with one or more antagonists of other cytokines (e.g. antibodies), including

but not limited to, IL-17A, IL-17F, IL-1β, IL-6 and TGF-β. *See, e.g.*, Veldhoen (2006) *Immunity* 24:179-189; Dong (2006) *Nat. Rev. Immunol.* 6(4):329-333. In various embodiments, an IL-23p19 binding compound of the invention is administered before, concurrently with, or after administration of the another antagonist or antagonists, such as an anti-IL-17A antibody. In one embodiment, an IL-17A binding compound is used in treatment of the acute early phase of an adverse immune response (e.g. MS, Crohn's Disease) alone or in combination with an IL-23 antagonist antibody of the present invention. In the latter case, the IL-17A binding compound may be gradually decreased and treatment with the antagonist of IL-23 alone is continued to maintain suppression of the adverse response. Alternatively, antagonists to IL-1β, IL-6 and/or TGF-β may be administered concurrently, before or after an IL-23p19 binding compound of the present invention. *See* Cua and Kastelein (2006) *Nat. Immunol.* 7:557-559; Tato and O'Shea (2006) *Nature* 441:166-168; Iwakura and Ishigame (2006) *J. Clin. Invest.* 116:1218-1222.

[0156] The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the inventions to the specific embodiments. The specific embodiments described herein are offered by way of example only, and the invention is to be limited by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

EXAMPLES

Example 1
General Methods

[0157] Standard methods in molecular biology are described. Maniatis *et al.* (1982) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Sambrook and Russell (2001) *Molecular Cloning, 3rd ed.*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Wu (1993) *Recombinant DNA*, Vol. 217, Academic Press, San Diego, CA. Standard methods also appear in Ausbel *et al.* (2001) *Current Protocols in Molecular Biology, Vols.1-4*, John Wiley and Sons, Inc. New York, NY, which describes cloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning in mammalian cells and yeast (Vol. 2), glycoconjugates and protein expression (Vol. 3), and bioinformatics (Vol. 4).

[0158] Methods for protein purification including immunoprecipitation, chromatography, electrophoresis, centrifugation, and crystallization are described. Coligan *et al.* (2000) *Current Protocols in Protein Science, Vol. 1*, John Wiley and Sons, Inc., New York. Chemical analysis, chemical modification, post-translational modification, production of fusion proteins, glycosylation of proteins are described. *See, e.g.*, Coligan *et al.* (2000) *Current Protocols in Protein Science, Vol. 2*, John Wiley and Sons, Inc., New York; Ausubel *et al.* (2001) *Current Protocols in Molecular Biology, Vol. 3*, John Wiley and Sons, Inc., NY, NY, pp. 16.0.5-16.22.17; Sigma-Aldrich, Co. (2001) *Products for Life Science Research*, St. Louis, MO; pp. 45-89; Amersham Pharmacia Biotech (2001) *BioDirectory*, Piscataway, N.J., pp. 384-391. Production, purification, and fragmentation of polyclonal and monoclonal antibodies are described. Coligan *et al.* (2001) *Current Protcols in Immunology, Vol. 1*, John Wiley and Sons, Inc., New York; Harlow and Lane (1999) *Using Antibodies*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Harlow and Lane, *supra*. Standard techniques for characterizing ligand/receptor interactions are available. *See, e.g.*, Coligan *et al.* (2001) *Current Protcols in Immunology, Vol. 4*, John Wiley, Inc., New York.

[0159] Methods for flow cytometry, including fluorescence activated cell sorting detection systems (FACS®), are available. *See, e.g.*, Owens *et al.* (1994) *Flow Cytometry Principles for Clinical Laboratory Practice*, John Wiley and Sons, Hoboken, NJ; Givan (2001) *Flow Cytometry, 2nd ed.*; Wiley-Liss, Hoboken, NJ; Shapiro (2003) *Practical Flow Cytometry*, John Wiley and Sons, Hoboken, NJ. Fluorescent reagents suitable for modifying nucleic acids, including nucleic acid primers and probes, polypeptides, and antibodies, for use, e.g., as diagnostic reagents, are available. Molecular Probes (2003) *Catalogue*, Molecular Probes, Inc., Eugene, OR; Sigma-Aldrich (2003) *Catalogue*, St. Louis, MO.

[0160] Standard methods of histology of the immune system are described. *See, e.g.*, Muller-Harmelink (ed.) (1986) *Human Thymus: Histopathology and Pathology*, Springer Verlag, New York, NY; Hiatt, *et al.* (2000) *Color Atlas of Histology*, Lippincott, Williams, and Wilkins, Phila, PA; Louis, *et al.* (2002) *Basic Histology:Text and Atlas*, McGraw-Hill, New York, NY.

[0161] Software packages and databases for determining, e.g., antigenic fragments, leader sequences, protein folding, functional domains, glycosylation sites, and sequence alignments, are available. *See, e.g.*, GenBank, Vector NTI® Suite (Informax, Inc, Bethesda,

MD); GCG Wisconsin Package (Accelrys, Inc., San Diego, CA); DeCypher® (TimeLogic Corp., Crystal Bay, Nevada); Menne *et al.* (2000) *Bioinformatics* 16: 741-742; Menne *et al.* (2000) *Bioinformatics Applications Note* 16:741-742; Wren *et al.* (2002) *Comput. Methods Programs Biomed.* 68:177-181; von Heijne (1983) *Eur. J. Biochem.* 133:17-21; von Heijne (1986) *Nucleic Acids Res.* 14:4683-4690.

Example 2

Humanization of Anti-human IL-23p19 Antibodies

[0162] The humanization of mouse anti-human IL-23p19 antibodies 6H12 and 7G10, was performed as essentially as described in PCT patent application publications WO 2005/047324 and WO 2005/047326.

[0163] Variable light and heavy domains of selected anti-IL-23 monoclonal antibodies (6H12 and 7G10) were cloned and fused to a human kappa light chain (CL domain) and human IgG1 heavy chain (CH1-hinge-CH2-CH3), respectively.

[0164] The amino acid sequence of the non-human VH domain was compared to a group of five human VH germline amino acid sequences; one representative from subgroups IGHV1 and IGHV4 and three representatives from subgroup IGHV3. The VH subgroups are listed in M.-P. Lefranc (2001) "Nomenclature of the Human Immunoglobulin Heavy (IGH) Genes", *Experimental and Clinical Immunogenetics* 18:100-116. 6H12 and 7G10 antibodies scored highest against human heavy chain germline DP-14 in subgroup VH1.

[0165] For all non-human antibodies, the VL sequences were of the kappa subclass of VL. The amino acid sequence of the non-human VL domain was compared to a group of four human VL kappa germline amino acid sequences. The group of four is comprised of one representative from each of four established human VL subgroups listed in V. Barbie & M.-P. Lefranc (1998) "The Human Immunoglobulin Kappa Variable (IGKV) Genes and Joining (IGKJ) Segments", *Experimental and Clinical Immunogenetics* 15:171-183 and M.-P. Lefranc (2001) "Nomenclature of the Human Immunoglobulin Kappa (IGK) Genes", *Experimental and Clinical Immunogenetics* 18:161-174. The four subgroups also correspond to the four subgroups listed in Kabat *et al.* (1991 - 5th Ed.) "Sequences of Proteins of Immunological Interest", U. S. Department of Health and Human Services, NIH Pub. 91-3242, pp. 103-130. 6H12 and 7G10 antibodies scored highest against human light chain germline Z-012 in subgroup VLkI.

[0166] An additional amino acid substitution was made in CDRH2 of antibody 6H12, wherein the D residue (Asp) in the parental rodent antibody (SEQ ID NO: 5) was replaced with an A residue (Ala) in the humanized form (SEQ ID NO: 1). This change was made to avoid a potential site for isoaspartate formation.

[0167] Once the target amino acid sequences of the variable heavy and light chains were determined, plasmids encoding the full-length humanized antibody were generated. Starting with a plasmid encoding a humanized anti-IL-10 antibody having VH3 DP-46 and VLkI Z-012 germline frameworks, the plasmids were altered using Kunkel mutagenesis (Kunkel (1985) *Proc. Natl. Acad. Sci. U.S.A* 82:488-492) to change the DNA sequence to the target humanized 6H12 or 7G10 sequences. Simultaneously, codon optimization was incorporated into the changes to provide for potentially optimal expression. The resulting humanized heavy and light chain sequences, including signal sequences, are provided at SEQ ID NOs: 1 and 2 (antibody 6H12) and at SEQ ID NOs: 3 and 4 (for antibody 7G10), respectively.

[0168] An analogous procedure was performed to determine the proper human frameworks for humanization of antibodies 10H11 and 22E9. Antibody 10H11 scored highest against human antibody heavy chain germline DP-46 in subgroup VH3 and light chain germline Z-A27 in subgroup VLkIII. Antibody 22E9 scored highest against human antibody heavy chain germline DP-14 in subgroup VH1 and light chain germline Z-B3 in subgroup VLkIV. The resulting humanized heavy and light chain variable domain sequences are provided at SEQ ID NOs: 89 and 90 (antibody 10H11) and at SEQ ID NOs: 91 and 92 (antibody 22E9), respectively.

[0169] An analogous procedure was performed to determine the proper human frameworks for humanization of antibody 17G8. With regard to the light chain, the humanized form of antibody 17G8 (SEQ ID NO: 131) is based on human antibody light chain germline subgroup I, the same as antibodies 7G10 and 6H12. With regard to the heavy chain, amino acid substitutions were also made in CDRH2 in the humanization process. One form of the humanized heavy chain of 17G8 (SEQ ID NO: 129) is based on human antibody heavy chain germline subgroup I, the same as antibodies 7G10 and 6H12, and has an N (Asn) to K (Lys) substitution at position 63 (N63K). Another form of the humanized heavy chain (SEQ ID NO: 130) is based on human antibody heavy chain germline subgroup III, and has N63K and I59Y substitutions. Residue numbering is

according to the Sequence Listing, not Kabat numbering. Humanized antibody 17G8 may comprise the light chain in conjunction with either form of the heavy chain, or with the original rodent CDRs (i.e. SEQ ID NO: 129 with a K63N substitution).

[0170] In yet another embodiment, humanized antibody 17G8 comprises a R98A substitution in the humanized 17G8 heavy chain sequence relative to the sequence disclosed at SEQ ID NOs: 129 and 130, which sequences are provided as SEQ ID NOs: 132 and 133, respectively. Residue 98 is not within a CDR as the CDR is typically defined in the Kabat nomenclature. When the R98A substitution is made in the 17G8 heavy chain sequence disclosed at SEQ ID NO: 129 the activity in the Ba/F3 proliferation bioassay improves (i.e. the IC50 decreases) over 1000-fold, to a level similar to the parental mouse antibody prior to humanization.

[0171] Humanized forms of other (rodent) antibodies disclosed herein may be constructed using the human frameworks disclosed for humanized antibodies 6H12, 7G10, 10H11, 22E9 or 17G8, or by repeating the procedure for selection of the best human frameworks by the methods disclosed in this Example. Substitution of the human frameworks disclosed herein as part of humanized antibodies 6H12, 7G10, 10H11, 22E9 or 17G8 is most appropriate for antibodies with CDR sequences similar to the respective humanized antibody, such as those falling into the same "sequence families" illustrated in the figures. "Sequence families" are the groupings of antibody sequences used to derive a consensus sequence.

Example 3

Determining the Equilibrium Dissociation Constant (K_d) for Humanized Anti-human IL-23 Using KinExA Technology

[0172] The equilibrium dissociation constant (K_d) for anti human IL-23 antibodies is determined using the KinExA 3000 instrument. Sapidyne Instruments Inc., Boise Idaho, USA. KinExA uses the principle of the Kinetic Exclusion Assay method based on measuring the concentration of uncomplexed antibody in a mixture of antibody, antigen and antibody-antigen complex. The concentration of free antibody is measured by exposing the mixture to a solid-phase immobilized antigen for a very brief period of time. In practice, this is accomplished by flowing the solution phase antigen-antibody mixture past antigen-coated particles trapped in a flow cell. Data generated by the instrument are analyzed using

custom software. Equilibrium constants are calculated using a mathematical theory based on the following assumptions:

[0173] 1. The binding follows the reversible binding equation for equilibrium:

$$k_{on} [Ab] [Ag] = k_{off}[AbAg]$$

2. Antibody and antigen bind 1:1 and total antibody equals antigen-antibody complex plus free antibody.

3. Instrument signal is linearly related to free antibody concentration.

[0174] 98 micron PMMA particles (Sapidyne, Cat No. 440198) are coated with biotinylated rhIL-23 according to Sapidyne "Protocol for coating PMMA particles with biotinylated ligands having short or nonexistent linker arms". To make biotinylated rhIL-23, EZ-link TFP PEO-biotin (Pierce, Cat. No. 21219) is used according to manufacturer's recommendations (Pierce bulletin 0874). Experimental procedures are done according to the KinExA 3000 manual.

[0175] Three forms of the heterodimeric IL-23 protein are used. Native or non-linked human IL-23 is comprised of two disulfide-linked chains, p19 and p40. "Non-linked" IL-23 is comprised of human p40 coexpressed in 293T cells with human p19:FLAG®-tag peptide and purified over an anti-FLAG® peptide affinity column.

[0176] "Elastikine" IL-23 is a single-chain peptide comprised of FLAG®-tag peptide:GLU-tag peptide:human p40:elasti-linker:human p19. The elasti-linker peptide sequence is derived from R&D Systems form of commercial IL-23. R&D Systems, Minneapolis, Minnesota, USA. Elastikine is expressed in 293T cells and purified over an anti-FLAG® peptide affinity column.

[0177] A non-tagged, non-linked form of native human IL-23p19/p40 coexpressed in SF9 cells is purchased from eBioscience (CAT No. 34-8239). eBioscience, San Diego, California, USA.

[0178] KinExA experiments are performed essentially as described at Example 3 of U.S. Patent Application Publication No. 2007/0048315. Table 4 shows the results of the KinExA analysis.

Table 4

K_d Values Determined by KinExA

Human IL-23	Antibody	K_d (pM)
elastikine	6H12	54, 48
non-linked	6H12	>1200
eBioscience	6H12	>1000, >920
elastikine	hu6H12	28, 36
elastikine	7G10	41, 9.2
elastikine	hu7G10	49, 16
elastikine	39G2	19
non-linked	39G2	34
eBioscience	39G2	620
elastikine	35F12	53
eBioscience	35F12	>700
elastikine	13B5	22
eBioscience	13B5	55
elastikine	7D7	2.7
elastikine	3D7	0.84
elastikine	49A10	7.4
elastikine	13F11	11
elastikine	33B12	6.8

Example 4

Determining the Equilibrium Dissociation Constant (K_d) for Humanized Anti-human IL-23p19 Antibodies Using BIAcore Technology

[0179] BIAcore determinations are performed essentially as described at Example 4 of U.S. Patent Application Publication No. 2007/0048315. Briefly, ligands (anti-IL-23 mAbs) are immobilized on a BIAcore CM5 sensor chip using standard amine-coupling procedure. IL-23 (various forms) is diluted in PBS to produce various concentrations. Kinetic constants for the various interactions are determined using BIAevaluation software 3.1. The K_d is determined using the calculated dissociation and association rate constants.

In certain experiments, proteins are used at the following concentrations: anti-IL-23 mAb hu7G10 in PBS at 0.33 mg/mL; anti-IL-23 mAb hu6H12 in PBS at 0.2 mg/mL; bac-wt human IL-23 in PBS at 0.30 mg/mL; eBioscience human IL-23 in PBS at 0.10 mg/mL; N222Q human IL-23 in PBS at 0.33 mg/mL.

[0180] In addition to the forms of IL-23 described in Example 3, other forms are also used. "Bac-wt" human IL-23 is identical to "elastikine" human IL-23 in sequence. This IL-23 is expressed in SF9 cells and purified over an anti-FLAG® peptide affinity column. "N222Q" human IL-23 is identical to "elastikine" human IL-23 in sequence except for alteration of Asn222 to Gln in the p40 subunit (GenBank Accession No. P29460). This IL-23 is expressed in SF9 cells and purified over an anti-FLAG® peptide affinity column.

[0181] Table 5 provides the K_d values as determined by BIAcore.

Table 5
K_d Determination by BIAcore

Human IL-23	Antibody	K_d (nM)
bac-wt	hu7G10	10
N222Q	hu7G10	0.3, 1.0
eBioscience	hu7G10	3.2, 9.0
bac-wt	hu6H12	5.1
N222Q	hu6H12	0.5
eBioscience	hu6H12	4.1

Example 5

Proliferation Bioassays for the Assessment of Neutralizing Anti-IL-23 Antibodies

[0182] The ability of a monoclonal antibody to biologically neutralize IL-23 is assessed by the application of short-term proliferation bioassays that employ cells that express recombinant IL-23 receptors. The IL-23R transfectant cell line (Ba/F3-2.2lo-hIL-23R) expresses both hIL-23R and hIL-12Rβ1, and is responsive to both human IL-23 and cynomolgus monkey IL-23. The transfectant Ba/F3-2.2lo cells proliferate in response to human IL-23 and the response can be inhibited by a neutralizing anti-IL-23 antibody. An antibody is titrated against a concentration of IL-23 chosen within the linear region of the dose-response curve, near plateau and above EC50. Proliferation, or lack thereof, is

measured by colorimetric means using Alamar Blue, a growth indicator dye based on detection of metabolic activity. The ability of an antibody to neutralize IL-23 is assessed by its IC50 value, or concentration of antibody that induces half-maximal inhibition of IL-23 proliferation.

[0183] Ba/F3 transfectants are maintained in RPMI-1640 medium, 10% fetal calf serum, 50 μM 2-mercaptoethanol, 2 mM L-Glutamine, 50 μg/mL penicillin-streptomycin, and 10 ng/mL mouse IL-3. Ba/F3 proliferation bioassays are performed in RPMI-1640 medium, 10% fetal calf serum, 50 μM 2-mercaptoethanol, 2 mM L-Glutamine, and 50 μg/mL penicillin-streptomycin.

[0184] Assays are performed in 96-well flat bottom plates in 150 μL per well. Anti-IL-23 antibodies are pre-incubated with IL-23 for 30-60 min, followed by addition of cells and incubation for 40-48 hours. Alamar Blue (Biosource Cat #DAL1100) is added and allowed to develop for 5-12 hours. Absorbance is then read at 570 nm and 600 nm (VERSAmax Microplate Reader, Molecular Probes, Eugene, Oregon, USA), and an $OD_{570-600}$ is obtained.

[0185] Cells are used in a healthy growth state, generally at densities of 3-8 x 10^5/mL. Cells are counted, pelleted, washed twice in bioassay medium, and suspended to the appropriate density for plating. An IL-23 dose response is performed using serial 1:3 dilutions (25:50 μL in bioassay medium) of IL-23. A neutralizing antibody dose response is also performed using serial 1:3 dilutions (25:50 μL in bioassay medium).

[0186] IC50 values are determined using GraphPad Prism® 3.0 software (Graphpad Software Inc., San Diego, California, USA), in which absorbance is plotted against cytokine or antibody concentration and IC50 values are determined using non-linear regression (curve fit) of sigmoidal dose-response.

[0187] Table 6 shows the IC50 values for blocking of Ba/F3 cell proliferation by anti-IL-23p19 antibodies. Values for multiple determinations are included for some antibodies, and values with standard deviations (± SD) are provided for others.

Table 6

IC50 Values for Blocking of Ba/F3 Cell Proliferation by Anti-IL-23 Antibodies

Antibody	Human IL-23	IC50 (pM)

7G10	elastikine	22, 18
7G10	non-linked	3000
7G10	eBioscience	3100, 510
hu7G10	elastikine	29
hu7G10	non-linked	10000
hu7G10	eBioscience	7800
6H12	elastikine	9, 11
6H12	non-linked	1500
6H12	eBioscience	1300, 500
hu6H12	elastikine	27
hu6H12	non-linked	4000
hu6H12	eBioscience	3200
13B5	elastikine	7, 5
13B5	non-linked	113
13B5	eBioscience	31
33B12	elastikine	4, 3
33B12	non-linked	193
33B12	eBioscience	57
39G2	elastikine	9, 5
39G2	non-linked	67
39G2	eBioscience	11
35F12	elastikine	15, 5
35F12	non-linked	73
35F12	eBioscience	12
3D7	elastikine	3, 3
3D7	non-linked	37
3D7	eBioscience	2
17G8	non-linked	3 ± 2
2G12	non-linked	183 ± 60
15G2	non-linked	133 ± 17
18E1	non-linked	48 ± 8
2C6	non-linked	11 ± 3
8E9	non-linked	8 ± 5
1D6	non-linked	16 ± 7

20A4	non-linked	5 ± 3
20H7	non-linked	3 ± 1
3C4	non-linked	12 ± 10
16F7	non-linked	141 ± 23
14A3	non-linked	135 ± 25
12C11	non-linked	57 ± 13

Example 6

Epitope for Anti-IL-23p19 Antibody 7G10

[0188] The epitope for the binding of antibody 7G10 to human IL-23p19 is determined by X-ray crystallography. Coordinates are determined for a complex of an Fab fragment of the chimeric form of antibody 7G10 and non-linked human IL-23, which comprises p19 and p40 subunits. Crystallization conditions are 12% polyethylene glycol 3350, 200 mM ammonium citrate, 100 mM HEPES-NaOH (pH 8). Crystals may also be obtained with other buffers at or around pH 8.

[0189] The sequence of human IL-23p19 is found at SEQ ID NO: 29 and the sequence of the mature form of human IL-12/IL-23 p40 is found at residues 23-328 of GenBank Accession No. P29460. The p40 subunit in the IL-23 used to determine the crystal structure is the N222Q variant, as described *supra*. The chimeric form of antibody 7G10 comprises i) a heavy chain comprising the mouse 7G10 V_H domain (SEQ ID NO: 6) fused to a human heavy chain constant region (residues 135 – 464 of SEQ ID NO: 3), and ii) a light chain comprising the mouse 7G10 V_L domain (SEQ ID NO: 18) fused to a human light chain constant region (residues 130 – 233 of SEQ ID NO: 4).

[0190] IL-23 amino acid residues within 4.0Å of residues on antibody 7G10 include E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139, L140. Additional residues K83, F90 and L110 are within 5.0Å. An amino acid residue on IL-23p19 is considered to be within a given distance of the antibody (e.g. 4.0Å or 5.0Å) if the coordinates of any atom of the residue are within the given distance of the coordinates of any atom of the antibody.

[0191] Most of these contacted residues fall into two main clusters along the primary structure of IL-23p19, with the first cluster comprising residues 82-95 (in which 11 of 14 residues are within 5.0Å of the antibody and 9 of 14 are within 4.0Å) and the second

cluster comprising residues 133-140 (in which 7 of 8 residues are within 4.0Å of the antibody). These clusters define epitopes comprising stretches of 8 or more contiguous amino acid residues of IL-23p19 in which 50%, 70% and 85% or more of the residues are within 5.0Å of the antibody.

[0192] Antibodies binding to either or both of these clusters would be expected to block binding of antibody 7G10. Given the strong sequence homology between all six CDR sequences (see FIGS. 1A – 1C and 2A – 2C), it is likely that the other antibodies in both the "(a)" light chain subfamily (conLA) and the heavy chain consensus subfamily (conH), i.e. antibodies 6H12, 13F11, 13B5, 13G1, 11C10, 7E2, 30F11, 6H4, 33D2, 2C6, 2G12, 18E1, 15G2, 17G8, will also bind to substantially the same epitope in IL-23p19 as antibody 7G10. The consensus CDR sequences for the antibodies of the "(a) light chain subfamily" variable domain sequence are provided at SEQ ID NOs: 68, 71 and 74. Corresponding heavy chain variable domain consensus sequences are provided at SEQ ID NOs: 65-67. Antibodies binding to the same epitope as antibody 7G10 would be expected to exhibit similar biological activities, such as blocking Ba/F3 cell proliferation in the assay described at Example 5 and Table 6, albeit with perhaps somewhat variable affinities and IC50s.

EXAMPLE 7

Mouse Splenocyte Assay for IL-23 Based on IL-17 Production

[0193] The biological activity of anti-IL-23p19 antibodies of the present invention is assessed using the splenocyte assay essentially as described in Aggarwal *et al.* (2003) *J. Biol. Chem.* 278:1910 and Stumhofer *et al.* (2006) *Nature Immunol.* 7:937. The mouse splenocyte assay measures the activity of IL-23 in a sample as a level of IL-17 production by murine splenocytes. The inhibitory activity of anti-IL-23p19 antibodies is then assessed by determining the concentration of antibody necessary to reduce the IL-23 activity in a given sample by 50% (the IC50). The IC50 as measured by this assay is greater than or equal to the equilibrium dissociation binding constant (K_d), i.e. the K_d may be equal to or lower than the IC50. As always, lower IC50 and K_d values reflect higher activities and affinities.

[0194] Briefly, spleens are obtained from 8-12 wk old female C57BL/6J mice (Jackson Laboratories, Bar Harbor, Maine, USA). Spleens are ground, pelleted twice, and filtered through a cell strainer (70 µm nylon). The recovered cells are cultured in 96-well plates (4 X 10^5 cells/well) in the presence of human IL-23 (10 ng/ml, ~170 pM) and mouse-

anti-CD3e antibodies (1 μg/ml) (BD Pharmingen, Franklin Lakes, New Jersey, USA), with or without the anti-IL-23p19 antibody to be assayed. Anti IL-23p19 antibodies are added at 10 μg/ml and at a series of 3-fold dilutions. Cells are cultured for 72 hours, pelleted, and the supernatant is assayed for IL-17 levels by sandwich ELISA.

[0195] IL-17 ELISA is performed as follows. Plates are coated with a capture anti-IL-17 antibody (100 ng/well) overnight at 4°C, washed and blocked. Samples and standards are added and incubated for two hours at room temperature with shaking. Plates are washed, and a biotinylated anti-IL-17 detection antibody (100 ng/well) is added and incubated for one hour at room temperature with shaking. The capture and detection antibodies are different antibodies that both bind to mouse IL-17 but do not cross-block. Plates are washed, and bound detection antibody is detected using streptavidin-HRP (horseradish peroxidase) and TMB (3,3',5,5'-tetramethylbenzidine). The plate is then read at 450-650 nm and the concentration of IL-17 in samples is calculated by comparison with standards.

[0196] Splenocyte assay IC50 values for several antibodies of the present invention are provided at Table 7. The antibodies tested show IC50s of 14-155 pM.

Table 7

Splenocyte Assay IC50s

Antibody Clone	IC50 (pM)
m17G8	18
m2G12	106
m15G2	95
m18E1	92
m2C6	37
m8E9	34
m1D6	27
m20A4	24
m20H7	33
m3C4	14
m16F7	155
m14A3	53

m12C11	79

[0197] Table 8 provides a brief description of the sequences in the sequence listing. SEQ ID NOs. 93-133 (*) are not disclosed in U.S. Patent Application Publication No. 2007/0048315. SEQ ID NOs. 77-80, 83 and 88 (**) are modified forms of SEQ ID NOs. 78-81, 84 and 89 of U.S. Patent Application Publication No. 2007/0048315 comprising additional variability at one or more positions.

Table 8

Sequence Identifiers

SEQ ID NO:	Description
1	hum6H12 HC
2	hum6H12 LC
3	hum7G10 HC
4	hum7G10 LC
5	m6H12 V_H
6	m7G10 V_H
7	m13F11 V_H
8	m13B5 V_H
9	m21A10 V_H
10	m33B12 V_H
11	m39G2 V_H
12	m35F12 V_H
13	m49A10 V_H
14	m3D7 V_H
15	m34F9 V_H
16	m7D7 V_H
17	m6H12 V_L
18	m7G10 V_L
19	m13F11 V_L
20	m13B5 V_L

21	m21A10 V_L
22	m33B12 V_L
23	m39G2 V_L
24	m35F12 V_L
25	m49A10 V_L
26	m34F9 V_L
27	m7D7 V_L
28	m3D7 V_L
29	Human IL23p19
30	Murine IL-23p19
31	m13G1 V_H
32	m11C10 V_H
33	m7E2 V_H
34	m30F11 V_H
35	m34E4 V_H
36	m6H4 V_H
37	m33D2 V_H
38	m1E10 V_H
39	m20A9 V_H
40	m22E9 V_H
41	m29D5 V_H
42	m5B12 V_H
43	m9C9 V_H
44	m11B10 V_H
45	m10G8 V_H
46	m19E9 V_H
47	m10H11 V_H
48	m13G1 V_L
49	m11C10 V_L
50	m7E2 V_L
51	m30F11 V_L

52	m34E4 V_L
53	m6H4 V_L
54	m33D2 V_L
55	m1E10 V_L
56	m20A9 V_L
57	m22E9 V_L
58	m29D5 V_L
59	m5B12 V_L
60	m9C9 V_L
61	m11B10 V_L
62	m10G8 V_L
63	m19E9 V_L
64	m10H11 V_L
65	CDRH1 Consensus
66	CDRH2 Consensus
67	CDRH3 Consensus
68	CDRL1(a) Consensus
69	CDRL1(b) Consensus
70	CDRL1(c) Consensus
71	CDRL2(a) Consensus
72	CDRL2(b) Consensus
73	CDRL2(c) Consensus
74	CDRL3(a) Consensus
75	CDRL3(b) Consensus
76	CDRL3(c) Consensus
77	CDRH1 Variable **
78	CDRH2 Variable **
79	CDRH3 Variable **
80	CDRL1(a) Variable **
81	CDRL1(b) Variable
82	CDRL1(c) Variable

83	CDRL2(a) Variable **
84	CDRL2(b) Variable
85	CDRL2(c) Variable
86	CDRL3(a) Variable
87	CDRL3(b) Variable
88	CDRL3(c) Variable **
89	hum10H11 V_H
90	hum10H11 V_L
91	hum22E9 V_H
92	hum22E9 V_L
93	m2G12 V_H *
94	m15G2 V_H *
95	m18E1 V_H *
96	m2C6 V_H *
97	m8E9 V_H *
98	m1D6 V_H *
99	m17G8 V_H *
100	m20A4 V_H *
101	m20H7 V_H *
102	m3C4 V_H *
103	m16F7 V_H *
104	m14A3 V_H *
105	m12C11 V_H *
106	m2G12 V_L *
107	m15G2 V_L *
108	m18E1 V_L *
109	m2C6 V_L *
110	m8E9 V_L *
111	m1D6 V_L *
112	m17G8 V_L *
113	m20A4 V_L *
114	m20H7 V_L *
115	m3C4 V_L *
116	m16F7 V_L *

117	m14A3 V_L *
118	m12C11 V_L *
119	V_H consensus A *
120	muIGHV1-14 germline *
121	muIGHJ2 germline *
122	muIGHJ3 germline *
123	V_L consensus A *
124	muIGKV5-39 germline *
125	V_L consensus B *
126	muIGKV8-30 germline *
127	V_L consensus C *
128	muIGKV3-12 germline *
129	hum17G8 V_H A *
130	hum17G8 V_H B *
131	hum17G8 V_L *
132	hum17G8 V_H A R98A*
133	hum17G8 V_H B R98A *

CLAIMS

WHAT IS CLAIMED IS:

1. A binding compound that binds to human IL-23, comprising:

at least one antibody light chain variable region, or antigen binding fragment thereof, comprising at least one CDR sequences selected from the group consisting of SEQ ID NOs: 80 - 88; and

at least one antibody heavy chain variable region, or antigen binding fragment thereof, comprising at least one CDR sequences selected from the group consisting of SEQ ID NOs: 77 - 79.

2. The binding compound of Claim 1, wherein:

the antibody light chain variable region, or antigen binding fragment thereof, comprises at least two CDR sequences selected from the group consisting of SEQ ID NOs: 80 - 88; and

the antibody heavy chain variable region, or antigen binding fragment thereof, comprises at least two CDR sequences selected from the group consisting of SEQ ID NOs: 77 - 79.

3. The binding compound of Claim 1, wherein:

the antibody light chain variable region, or antigen binding fragment thereof, has at least three CDR sequences selected from the group consisting of SEQ ID NOs: 80 - 88; and

the antibody heavy chain variable region, or antigen binding fragment thereof, has CDR sequences SEQ ID NOs: 77 - 79.

4. The binding compound of Claim 3, comprising:

at least one CDRL1 selected from the group consisting of SEQ ID NOs: 80 - 82;
at least one CDRL2 selected from the group consisting of SEQ ID NOs: 83 - 85; and
at least one CDRL3 selected from the group consisting of SEQ ID NOs: 86 – 88.

5. The binding compound of Claim 4, comprising:

CDRL1 selected from the group consisting of SEQ ID NOs: 68 - 70;
CDRL2 selected from the group consisting of SEQ ID NOs: 71 - 73;
CDRL3 selected from the group consisting of SEQ ID NOs: 74 – 76;
CDRH1 of SEQ ID NO: 65;
CDRH2 of SEQ ID NO: 66; and
CDRH3 of SEQ ID NO: 67.

6. A binding compound that binds to human IL-23, comprising:

an antibody light chain variable region, or antigen binding fragment thereof, comprising:

at least one CDRL1 from the group consisting of SEQ ID NOs: 68 – 70 or a variant thereof;

at least one CDRL2 from the group consisting of SEQ ID NOs: 71 – 73 or a variant thereof;

at least one CDRL3 from the group consisting of SEQ ID NOs: 74 - 76 or a variant thereof; and

an antibody heavy chain variable region, or fragment thereof, comprising the CDR sequences of SEQ ID NOs: 65 – 67 or a variant thereof;

wherein each variant comprises up to five conservatively modified amino acid substitutions.

7. The binding compound of Claim 6 wherein:
CDRL1 comprises the sequence of SEQ ID NO: 68 or a variant thereof;
CDRL2 comprises the sequence of SEQ ID NO: 71 or a variant thereof; and
CDRL1 comprises the sequence of SEQ ID NO: 74 or a variant thereof.

8. A binding compound that binds to human IL-23, comprising:

an antibody light chain variable region, or antigen binding fragment thereof, comprising the sequence of residues 20-129 of SEQ ID NO: 2 or 4, or a variant thereof; and

an antibody heavy chain variable region, or antigen binding fragment thereof, comprising the sequence of residues 20-134 of SEQ ID NO: 1 or 3, or a variant thereof;

wherein each variant comprises up to 20 conservatively modified amino acid substitutions.

9. The binding compound of Claim 8, wherein the binding compound is an antibody or antigen binding fragment thereof comprising:

a light chain variable region comprising residues 20-129 of SEQ ID NO: 2 or 4; and

a heavy chain variable region comprising residues 20-134 SEQ ID NO: 1 or 3.

10. The binding compound of Claim 8, comprising:

a light chain consisting essentially of the mature form (residues 20-233) of SEQ ID NO: 2; and

a heavy chain consisting essentially of the mature form (residues 20-464) of SEQ ID NO: 1.

11. A binding compound that binds to human IL-23 at an epitope comprising residues 82-95 or residues 133-140 of SEQ ID NO: 29.

12. The binding compound of Claim 11, wherein the binding compound binds to an epitope comprising of residues 82-95 and residues 133-140 of SEQ ID NO: 29.

13. The binding compound of Claim 12, wherein the binding compound binds to an epitope comprising residues E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139 and L140 of SEQ ID NO: 29.

14. A binding compound that binds to human IL-23, comprising:

a light chain variable region having at least 90% homology to residues 20 – 129 of SEQ ID NO: 2 or 4; and

a heavy chain variable region having at least 90% homology to residues 20 – 134 of SEQ ID NO: 1 or 3.

15. An antibody that is able to block binding of the binding compound of Claim 4 to human IL-23 in a cross-blocking assay.

16. The binding compound of Claim 4 wherein the binding compound blocks IL-23 mediated activity.

17. An isolated nucleic acid encoding at least one of the light chain variable region or heavy chain variable region of the binding compound of Claim 4.

18. An expression vector comprising the nucleic acid of Claim 17 operably linked to control sequences that are recognized by a host cell when the host cell is transfected with the vector.

19. A host cell comprising the expression vector of Claim 18.

20. A method of producing a polypeptide comprising:

culturing the host cell of Claim 19 in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable regions; and

recovering the polypeptides from the host cell or culture medium.

21. The binding compound of Claim 4, further comprising a heavy chain constant region comprising a γ1 human heavy chain constant region or a variant thereof, wherein the variant comprises up to 20 conservatively modified amino acid substitutions.

22. The binding compound of Claim 4, further comprising a heavy chain constant region comprising a γ4 human heavy chain constant region or a variant thereof, wherein the variant comprises up to 20 conservatively modified amino acid substitutions.

23. The binding compound of Claim 4, wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, $F(ab')_2$, and a diabody.

24. A method of suppressing an immune response in a human subject comprising administering to a subject in need thereof an antibody specific for IL-23, or a antigen binding fragment thereof, in an amount effective to block the biological activity of IL-23, wherein the antibody is the antibody of claim 4.

25. The method of claim 24, wherein the immune response is an inflammatory response.

26. The method of claim 25, wherein the subject has a disorder selected from the group consisting of arthritis, psoriasis and inflammatory bowel disease.

27. The method of claim 24, wherein the immune response is an autoimmune response.

28. The method of claim 27, wherein the subject has a disorder selected from the group consisting of multiple sclerosis, systemic lupus erythematosus and diabetes.

29. The method of claim 24, wherein the subject has cancer and the immune response is a Th17 response.

30. The method of claim 24, further comprising administering an immunosuppressive or anti-inflammatory agent.

31. A pharmaceutical composition comprising the binding compound of Claim 4 in combination with a pharmaceutically acceptable carrier or diluent.

32. The pharmaceutical composition of claim 31, further comprising an immunosuppressive or anti-inflammatory agent.

33. A binding compound that binds to human IL-23, comprising:
an antibody light chain variable region, or antigen binding fragment thereof, comprising:

CDRL1 comprising residues 24 – 34 of SEQ ID NO: 112, or a variant thereof;

CDRL2 comprising residues 50 – 56 of SEQ ID NO: 112, or a variant thereof;

CDRL3 comprising residues 89 – 97 of SEQ ID NO: 112, or a variant thereof; and

an antibody heavy chain variable region, or fragment thereof, comprising:

CDRH1 comprising residues 26 – 35 of SEQ ID NO: 99, or a variant thereof;

CDRH2 comprising residues 50 – 66 of a sequence selected from the group consisting of SEQ ID NOs: 99, 129 and 130, or a variant thereof; and

CDRH3 comprising residues 99 – 104 of SEQ ID NO: 99, or a variant thereof;

wherein each variant comprises up to five conservatively modified amino acid substitutions.

34. The binding compound of Claim 33 wherein the binding compound comprises: an antibody light chain variable region, or antigen binding fragment thereof, comprising:

CDRL1 comprising residues 24 – 34 of SEQ ID NO: 112;

CDRL2 comprising residues 50 – 56 of SEQ ID NO: 112;

CDRL3 comprising residues 89 – 97 of SEQ ID NO: 112; and

an antibody heavy chain variable region, or fragment thereof, comprising:

CDRH1 comprising residues 26 – 35 of SEQ ID NO: 99;

CDRH2 comprising residues 50 – 66 of a sequence selected from the group consisting of SEQ ID NOs: 99, 129 and 130; and

CDRH3 comprising residues 99 – 104 of SEQ ID NO: 99.

35. A binding compound that binds to human IL-23, comprising:

an antibody light chain variable region, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 131, or a variant thereof; and

an antibody heavy chain variable region, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 129, 130, 132 or 133, or a variant thereof;

wherein each variant comprises up to 20 conservatively modified amino acid substitutions.

36. The binding compound of Claim 35, wherein the binding compound is an antibody or antigen binding fragment thereof comprising:

a light chain variable region comprising the sequence of SEQ ID NO: 131; and

a heavy chain variable region comprising the sequence of SEQ ID NO: 129, 130, 132 or 133.

37. The binding compound of Claim 35, comprising:

a light chain variable region consisting essentially of the sequence of SEQ ID NO: 131; and

a heavy chain variable region consisting essentially of the sequence of SEQ ID NO: 129, 130, 132 or 133.

38. The binding compound of Claim 33, wherein the binding compound binds to human IL-23 at an epitope comprising residues 82-95 and residues 133-140 of SEQ ID NO: 29.

39. A binding compound that binds to human IL-23, comprising:

a light chain variable region having at least 90% homology to the sequence of SEQ ID NO: 131; and

a heavy chain variable region having at least 90% homology to the sequence of SEQ ID NO: 129, 130, 132 or 133.

40. An antibody that is able to block binding of the binding compound of Claim 36 to human IL-23 in a cross-blocking assay.

41. The binding compound of Claim 33 wherein the binding compound blocks IL-23 mediated activity.

42. An isolated nucleic acid encoding at least one of the light chain variable region or heavy chain variable region of the binding compound of Claim 33.

43. An expression vector comprising the nucleic acid of Claim 42 operably linked to control sequences that are recognized by a host cell when the host cell is transfected with the vector.

44. A host cell comprising the expression vector of Claim 43.

45. A method of producing a polypeptide comprising:

culturing the host cell of Claim 44 in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable regions; and

recovering the polypeptides from the host cell or culture medium.

46. The binding compound of Claim 33, further comprising a heavy chain constant region comprising a γ1 human heavy chain constant region or a variant thereof, wherein the constant region variant comprises up to 20 conservatively modified amino acid substitutions.

47. The binding compound of Claim 33, further comprising a heavy chain constant region comprising a γ4 human heavy chain constant region or a variant thereof, wherein the constant region variant comprises up to 20 conservatively modified amino acid substitutions.

48. The binding compound of Claim 33, wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, $F(ab')_2$, and a diabody.

49. A method of suppressing an immune response in a human subject comprising administering to a subject in need thereof an antibody specific for IL-23, or a antigen binding fragment thereof, in an amount effective to block the biological activity of IL-23, wherein the antibody is the antibody of claim 33.

50. The method of claim 49, wherein the immune response is an inflammatory response.

51. The method of claim 50, wherein the subject has a disorder selected from the group consisting of arthritis, psoriasis and inflammatory bowel disease.

52. The method of claim 49, wherein the immune response is an autoimmune response.

53. The method of claim 52, wherein the subject has a disorder selected from the group consisting of multiple sclerosis, systemic lupus erythematosus and diabetes.

54. The method of claim 49, wherein the subject has cancer and the immune response is a Th17 response.

55. The method of claim 49, further comprising administering an immunosuppressive or anti-inflammatory agent.

56. A pharmaceutical composition comprising the binding compound of Claim 33 in combination with a pharmaceutically acceptable carrier or diluent.

57. The pharmaceutical composition of claim 56, further comprising an immunosuppressive or anti-inflammatory agent.

```
                                         ---CDRH1--
7G10   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSNVMH WVKQKPGQGLEWIG
6H12   EVHLQQSGPELVKPGASVKMSCKAS GYTFNRYLIH WVKQKPGQGLEWIG
13F11  EVQLQQSGPELVKPGASVKMSCKAS GHTLTRYLMH WVQQKPGQGLEWIG
13B5   EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYLMH WVKQKPGQGLEWIG
7E2    EVQLQQSGPELVKPGASVKMSCKAS GYTFTTYLMH WVKQKPGQGLEWIG
13G1   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYLMH WVKQKPGQGLEWIG
11C10  EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYVMH WVKQKPGQGLEWIG
1E10   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
30F11  EVQLQQSGPELLKPGASVKMSCKAS AYTFTRYLIH WVKQKPRQGLEWIG
5B12   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
6H4    EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYLMH WVKQKPGQGLEWIG
9C9    EVQLQQSGPELVKPGASVRMSCKAS GYTFTSYLIH WVKQKPGQGLEWIG
11B10  EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
33D2   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYLMH WVKQKPGQGLEWIG
20A9   EVQLKQSGLEVVKPGASVKMSCKAS GYTFTAHLMH WVKQRPGQGLEWIG
22E9   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG
29D5   EVQLQQSGPELVKPGASVKMSCKAS GYSFTSYVMH WVKQKPGQGLEWIG
21A10  EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLDWIG
2G12   EVQLQQSGPELVKPGASVKMSCKAS GYTFTCCILH WVKQKPGQGLEWIG
15G2   EVQLQQSGPELVKPGASVKMSCKAS GYTFTNYLMH WVKQKPGQGLEWIG
18E1   EVQLQQSGPELVKPGASVKMSCKAS GNTFTRYVMN WVKQKPGQGLEWIG
2C6    EVQLQQSGPELVKPGASVKMSCKAS GYTFTRYLIH WVKQKPGQGLEWIG
conH   EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYLMH WVKQKPGQGLEWIG
                                     R VI
V1-14  EFQLQQSGPELVKPGASVKMSCKAS GYTFTSYVMH WVKQKPGQGLEWIG

49A10  EVQLQQSGPELVKPGASVKISCKAS GYTFTDYYMN WVKQSHGKSLEWFG
34E4   EVQLQQSGPELVKPGASVKMSCKAS GYTFTAYNMH WVKQSHGKSLEWIG
8E9    EVQLQQSGPELVKPGASVKMSCKAS GYTFTAYLIH WVKQSHGKSLEWIG
1D6    EVQLQQSGPDLVKPGASVKMSCKAS GYTFTAYLIH WVKRSHGKSLDWIG

34F9   QVQLQQSGAELAKPGASVKLSCKAS GYTFPTFWMH WVKQRPGQGLEWIG
7D7    QVQLQQSGAELAKPGASVKLSCKAS GYTFTNYWMD WVKQRPGQGLEWIG

33B12  QVQLQQSGAELARPGASVKLSCKAS GYTFTSYSLK WVKQRTGQGLEWIG
17G8   QAQLQQSGSELARPGASVKLSCKAS GYTFTSYGIK WVKQRTGQGLEWIG
20A4   QAQLQQSGGELARPGASVKLSCKAS GYTFTSYGIK WVKQGTGQGLEWIG
20H7   QAQLQQSGGELARPGASVKLSCKAS GYTFTNYGIK WVKQRTGQGLEWIG
3C4    QVQLQQSGGELARPGASVKLSCKAS GYTFTSYGIK WVKQRFGQGLEWIG

3D7    QVQLQQSGPELVKPGASVKISCKAS GYSFTSYYIH WVKQRPGQGLEWIG

39G2   QVQLQQPGAELVRPGASVKLSCKAS GYSFTSSWMN WVKQRPGQGLEWIG
35F12  QVQLQQPGAELMRPGASVRLSCKAS GYSFTTSWMN WVKQRPGQGLEWIG

14A3   EVILVESGGGFVKPGGSLKLSCAAS GFTFSNYGMS WVRQTPDKGLEWVA
12C11  EVMLVESGGGLVKPGGSLKLSCAAS GFTFSNYGMS WVRQSPERGLEWVA

10H11  EVMLVESGGGLVKPGGSLKLSCAAS GFTFSSYSMS WVRQTPEKRLEWVA
19E9   EVMLVESGGGLVKPGGSLKLSCAAS GFTFSTYDMS WVRQTPEKRLEWVA
10G8   EVMLVESGGGLVKPGGSLKLSCAAS GFTFSSYSMS WVRQTPEKRLEWVA

16F7   EVQLVESGGDLVKPGGSLKLSCAAS GFIFNSYGMS WVRQTPDKRLEWVA
```

Figure 1A

```
       ------CDRH2------
7G10   YINPYNDGTKYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR
6H12   YINPNNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAA
13F11  YINPYNDGTKYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR
13B5   YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR
7E2    YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCTK
13G1   YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMDLSSLTSEDSAVYYCAI
11C10  YINPYNDVPNYNENFKG KATLTSDKSSSTASMELSSLTSEDSAVYYCAV
1E10   YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAS
30F11  YINPYNDGTKYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR
5B12   YINPYNDGTNYNEKFKH KATLTSDKSSSTAYMELSSLTSEDSAVYYCTS
6H4    YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR
9C9    YINPYNDGTNYNENFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAS
11B10  YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELGSLTSEDSAVYYCAS
33D2   YINPYNDGPKYNEQFKG KATLTSDKSSNTAYMELSSLTSEDSAVYYCAR
20A9   YINPYNDGTNYNEKFKG KATLTSDKSSSTAFMELSSLTSEDSAVYYCAS
22E9   YINPYNAGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAS
29D5   YINPYNDGTNYNEKFRG KATLTSDKSSNTAYLDLSSLTSEDSAVYYCAS
21A10  YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCTS
2G12   YINPYNDGTKYNEKFKG KATLTSDKSSRTAYMELSSLTSEDSAVYYCAR
15G2   YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAIYFCTS
18E1   YINPYNDGTNYNEKFKG KATLTSDKSSTTAYMELSSLTSEDSAVYYCVH
2C6    YVNPYNDGTNYNEKFRG KATLTSDKSSSTAYMELSSLTSEDSAVYYCTS
conH   YINPYNDGTNYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAS
                K                                  TR
V1-14  YIYPYNDGTKYNEKFKG KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR

49A10  DINPNNGDTSYNQKFKG KATLTVDKSSSTAYMELRSLTSEDSADYYCAR
34E4   YINPNNGIPNYNQKFKG KATLTVNKSSSTAYMELRSLTSEDSAVFYCAL
8E9    YINPNNGGTNYNQKFKD KATLTVNKSSATAYMELRSLTSEDSAVFYCSS
1D6    YINPNDGVTSYNQKFKG KATLTVNKSSGTAYMELRSLTSEDAAVYYCTL

34F9   YINPSSGYTEYNQKFKD KATLTADKSSSTAYMQLSSLTYEDSAVYYCAR
7D7    YINPSSGYVEYNQKFKY KATLTADKTSSTAYMQLSSLTYDDSAVYYCAR

33B12  EIHPRSGNTHYNEKFKG KATLTADKSSSTAYMDLRSLTSEDSAVYFCAT
17G8   EIFPRSGQTIYNENFKG KATLTADKSSSTAYMELRSLTSEDSAVYFCAA
20A4   EIFPRSGQTYYNEKFKG KATLTADKSSSTAYMELRSLTSEDSAVYFCAS
20H7   EIFPRSGQTIYNEKFKG KATLTADKSSSTAYMELRSLTFEDSAVYFCAA
3C4    EIFPRGGNTYYNEKFKG KATLTADKSSSTAYMELRSLTSEDSAVYFCTA

3D7    WIFPGSGNTKYNEKFKG KATLTADTSSTTAYMQLSSLTSEASAVYFCAR

39G2   MIHPSDSETRTNQKFKD KATLTVDKSSSTAYMQLSSPTSEDSAVYYCAR
35F12  MIHPSDSETRLNQNFKD KATLTVDRSSSTAYMQLNSPTSEDSAVYYCAR

14A3   TISTGGRYIYYSDTVKG RFTISRDNAKSTLYLKMSSLRSEDTAVHFCAR
12C11  TISTGGRYTFYSDTVKG RFTISRDNARNTLYLKMSSLISEDTAVHYCAR

10H11  TISRGGGNTYYPDSVKG RFTISRDNANNNLFLRLSSLRSEDTALYYCAR
19E9   TISRGGGNTYYPDSVKS RFTISRDNAKNNLYLQMSSLRSVDTALYYCSR
10G8   TISRGGGNTYYPDSVKG RFTISRDNAKNNLYLRMSSLRSEDTALYYCAR

16F7   TISSGGRNTYYPDSVKG RFTISRDNAKNTLYLQMSSLKSEDTAMYYCAR
```

Figure 1B

```
        -----CDRH3-----
7G10    NWDVAY              WGQGTLVTVSA
6H12    NWDQAY              WGQGTLVTVSA
13F11   NWDVAY              WGQGTLVTVSA
13B5    NWDVGGY             WGQGTTLTVSS
7E2     NWDKGY              WGQGTTLTVSS
13G1    NWDLAY              WGQGTLVTVSA
11C10   -WDFTY              WGQGTLVTVSA
1E10    NWDVGY              WGQGTTLTVSS
30F11   NWDVAY              WGQGTLVTVSA
5B12    NWDVGF              WGQGTTLTVSS
6H4     NWDVTC              WGQGTLVTVSA
9C9     NWDVGY              WGQGTTLTVSS
11B10   NWDVGY              WGQGTTLTVSS
33D2    NWDVTC              WGQGTLVTVSA
20A9    NWDVGY              WGQGTTLTVSS
22E9    NWDVGY              WGQGTTLTVSS
29D5    NWDVGY              WGQGTTLTVSS
21A10   NWDRGY              WGQGTTLTVSS
2G12    RWDEAY              WGQGTLVTVSA
15G2    NWDLDY              WGQGTTLTVSS
18E1    NWDLDY              WGQGTTLTVSS
2C6     NWDLNY              WGQGTTLTVSS
---------------------------------------
conH    NWDVGY              WGQGTTLTVSS
           LA                    LV   A

D-Q52   NWD

J2         YFDY             WGQGTTLTVSS

J3         WFAY             WGQGTLVTVSA

49A10   PHYRNWYFDV          WGTGTTVIVSS
34E4    NWDLDY              WGQGTTLSVSS
8E9     NWDLDY              WGRGTTLTVSS
1D6     NWDLDY              WGQGTTLTVSS

34F9    SPPYYYDSTYWSFDV     WGTGTAVTVSS
7D7     SPPYYYANTYWSFDV     WGTGTTVTVSS

33B12   NWDLGY              WGQGTTITVSS
17G8    NWDLDY              WGQGTILTVSS
20A4    NWDLDY              WGQGTILTVSS
20H7    NWDLDY              WGQGTILTVSS
3C4     NWDLDY              WGQGTTLTVSS

3D7     EGLHYFGLYAMDY       WGHGTSVTVSS

39G2    GMITAPTVY           WGQGTLVTVSA
35F12   GMITAPSVY           WGQGTLVTVSA

14A3    HEGDRYYGWYFDV       WGAGTTVTVSS
12C11   HEGDTYYGWYFDV       WGAGTTVTVSS

10H11   WPFSYGMDY           WGQGTSVTVSS
19E9    WPFSYAMDY           WGQGTSVTVSS
10G8    WPFSYGMDY           WGQGTSVTVSS

16F7    QGGYEGYVDV          WGIGTTVTVSS
```

Figure 1C

```
                                ------CDRL1------
7G10   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
6H12   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
33B12  DIVLTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
13F11  DIVMTQSPATLSVTPGDRVSLSC RASQ------TISDYLH
13B5   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
13G1   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
11C10  DIVMTQSPATLSVTPGDRVSLSC RASQ------RISDYLY
7E2    DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
30F11  DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
34E4   DIVMTQSPATLSVTPGDRVSLSC RASQ------SIRDYLY
6H4    DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
33D2   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
2C6    DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLY
2G12   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISAYLH
1D6    DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
18E1   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISHYLY
15G2   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
17G8   DIMMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
20A4   DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDFLH
20H7   DIMMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
3C4    DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH
8E9    DIVMTQSPATLSVTPGDRVSLSC RASQ------SIGDYLH
conLA  DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH

m5-39  DIVMTQSPATLSVTPGDRVSLSC RASQ------SISDYLH

1E10   DIVMSQSPSSLAVSVGEKITMTC KSSQTLLYSSNQKNFLA
20A9   DIVMSQSPSSVAVSVGEKVTMSC KSSQSLLYSSNQKNFLA
22E9   DIVMSQSPSSVAVSVGEKVTMSC KSSQSLLYSSNQKNFLA
29D5   DIVMSQSPSSQTVSVGERVTMSC KSSQSLLYSSNQKNFLA
5B12   DIVMSQSPSSLAVSVGEKVTMNC KSSQSLLYSTNQKNFLA
9C9    DIVMSQSPSSLPVSVGEKVTMSC KSSQSLLYSSSQKNYLA
11B10  DIVMSQSPSSVAVSVGEKVTMNC KSSQNLLYSSNQKNFLA
conLB  DIVMSQSPSSLAVSVGEKVTMSC KSSQSLLYSSNQKNFLA
                 V

m8-30  DIVMSQSPSSLAVSVGEKVTMSC KSSQSLLYSSNQKNYLA

16F7   DIVMTQSHRFMSTSVGDRVSITC KASQ------DVSSAVA

3D7    DIQMTQTTSSLSASLGDRVTISC SASQGISN------YLN

21A10  DIQMTQSPASLSASVGETVTITC RASGNIHN------YLT

14A3   DIVLTQSPASLAVSLGQRATISC KASQSVDY--DGESYMN
12C11  DIVLTQSPASLAVSLGQRATISC KASHSVDY--DVDSFMN

10G8   DIVLTQSPASFAVALGQRATISC RASKSVST--SDYSYMH
19E9   DIVLTQSPTSLAVSLGQRATISC RASKSVST--SDYSYMH
10H11  DIVLTQSPASLAVALGQRATISC RASKSVST--SDYSYMH
39G2   DIVLTQSPASLAVSLGQRATISC RASKSVST--SAYSYFH
35F12  DIVLTQSPASLAVSLGQRATISC RASKSVST--SAYSYFH
49A10  DIVLTQSPASLVVSLGQRATISC RASKSVST--SGYSFLN
34F9   DIGLTQSPASLAVSLGQRATISC RASKSVSA--FGYNYMH
7D7    DIGLTQSPASLAVSLGQRATISC RASKSVST--SGYSFMH
conLC  DIVLTQSPASLAVSLGQRATISC RASKSVST--SDYSYMH
                                           G

m3-12  DIVLTQSPASLAVSLGQRATISC RASKSVST--SGYSYMH
```

Figure 2A

```
                         -CDRL2-
7G10   WYRQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
6H12   WYQQKSHESPRLLIK YTSQSIS GIPSRFSGSGSGS
33B12  WFQQRSHESPRLLIK YASQSIS GIPSRFSGSGSGS
13F11  WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
13B5   WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
13G1   WYQQKSHESPRLLIK FASQSIS GIPSRFSGSGSGS
11C10  WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
7E2    WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
30F11  WYQQKSHESPRLLIK YASQSIS GIPTRFSGSGSGS
34E4   WYQQKSHESPRLLIK FASQSIS GIPSRFSGSGSGS
6H4    WYHQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
33D2   WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
2C6    WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
2G12   WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
1D6    WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
18E1   WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
15G2   WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
17G8   WYRQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
20A4   WYRQKSHESPRLLIK YVSQSIS GIPSRFSGSGSGS
20H7   WYRQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
3C4    WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS
8E9    WYQQKLHESPRLLIK YASRSIS GIPSRFSGSGSGS
conLA  WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS

m5-39  WYQQKSHESPRLLIK YASQSIS GIPSRFSGSGSGS

1E10   WYRQKPGQSPKLLIY WTSTRES GVPDRFTGSGSGT
20A9   WYQQKPGQSPKLLIF WTSTRKS GVPDRFTGSGSGT
22E9   WYQQKPGQSPKLLIY WASTRES GVPDRFTGSGSGT
29D5   WYQQKPGQSPKLLIH WASTRES GVPDRFTGSGSGT
5B12   WYQQKPGQSPKLLIY WASTRKS GVPDRFTGSGSGT
9C9    WSQQKPGQSPKLLIY WASTRKS GVPDRFTGSGSGT
11B10  WYQQKPGQSPKLLIY WASTRKS GVPDRFTGSGSGT
conLB  WYQQKPGQSPKLLIY WASTRKS GVPDRFTGSGSGT
                             E
m8-30  WYQQKPGQSPKLLIY WASTRES GVPDRFTGSGSGT

16F7   WYQQKPGQSPNLLIY SASFRNT GVPDRFTGSGSGT

3D7    WFQQKPDGTVKLLIY YTSSLHS GVPSRFSGSGSGT

21A10  WYQQKQGKSPQLLVY NAKTLAD GVPSRFSGSGSGT

14A3   WYQQKPGQPPKLLIY TSSSLAS GIPARFSGSGSGT
12C11  WYQQKPGQPPKLLIF ASSSLES GIPARFSGSGSGT

10G8   WYQQKPGQPPKLLIY LASNLDS GVPARFSGSGSGT
19E9   WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
10H11  WYQQKPGQPPKLLIY LASNLDS GVPARFSGSGSGT
39G2   WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
35F12  WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
49A10  WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
34F9   WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
7D7    WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
conLC  WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT

m3-12  WYQQKPGQPPKLLIY LASNLES GVPARFSGSGSGT
```

Figure 2B

		--CDRL3--	
7G10	DFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
6H12	DFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
33B12	DFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
13F11	HFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
13B5	DFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
13G1	DFTLSINSVEPEDVGVYYC	QNGHSFPYT	FGGGTKLEIKR
11C10	DFTLSINSVEPEDVGVYYC	QNGHSFPYT	FGGGTKLEIKR
7E2	EFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
30F11	DFTLTINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
34E4	DFTLSINSVEPEDVGVYYC	QNGHSFPYT	FGGGTKLEIKR
6H4	DFTLTINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
33D2	DFTLSINSVEPEDVGVYYC	QNGHSFPFT	FGSGTKLEIKR
2C6	DFTLSINSVEPEDVGVYFC	QNGHSFPFT	FGSGTKLEIKR
2G12	DFTLSINSVEPEDVGIYYC	QNGHSFPFT	FGSGTKLEIKR
1D6	DFTLSITNVEPEDVGIYYC	QNGHSFPFT	FGSGTKLEIKR
18E1	DFTLSINSVEPEDVGMYYC	QNGHSFPYT	FGGGTKLEIKR
15G2	DFILNINSVEPEDVGVYYC	QNGHSFPYT	FGGGTKLEIKR
17G8	DFTLSINSVEPEDVGIYYC	QNGHSFPYT	FGGGTKLEIKR
20A4	DFTLSINSVDPEDVGVYYC	QNGHSFPYT	FGGGTKLEIKR
20H7	DFTLSINSVEPEDVGVYFC	QNGHSFPYT	FGGGTKLEIKR
3C4	DFTLSINSVESEDVGVYYC	QNGHSFPFT	FGSGTKLKIKR
8E9	YFTLSINSVEAEDVGVYFC	QNGHSFPFT	FGSGTKLEIKR
conLA	DFTLSINSVEPEDVGVYYC	QNGHSFPFT	
m5-39	DFTLSINSVEPEDVGVYYC	QNGHSFP	
1E10	DFTLTISSVKAEDLAVYYC	QQYYSYPFT	FGSGTKLEIKR
20A9	DFTLTISSVKAEDLAVYYC	QQYYSYPFT	FGSGTKLEIKR
22E9	DFILTISSVRAEDLAFYYC	QQYYSYPFT	FGSGTKLEIKR
29D5	DFTLTISSVKAEDLALYYC	QQYYSYPFT	FGSGTKLEIKR
5B12	DFTLTISSVKAEDLAVYYC	QQYYSYPFT	FGSGTKLEIKR
9C9	DFTLTISSVKAEDLAVYYC	HQYYSYPFT	FGSGTKLEIKR
11B10	DFTLTISSVRAEDLAFYYC	QQYYSYPFT	FGSGTKLEIKR
conLB	DFTLTISSVKAEDLAVYYC	QQYYSYPFT	
m8-30	DFTLTISSVKAEDLAVYYC	QQYYSYP	
16F7	DFTFTISGVQAEDLAVYYC	QQHHSTPLT	FGAGTKLELKR
3D7	DYSLTISNLEPEDIATYYC	QQYSKLPYT	FGGGTKLEIKR
21A10	QFSLKINSLQPEDFGSYYC	QHFWSTPFT	FGSGTKLEIKR
14A3	NFTLNIHPVEEEDAATYCC	QQGNEDLFT	FGSGTKLEIKR
12C11	NFILNIHPVEEEDAATYYC	QQGNEDLFT	FGSGTKLEIKR
10G8	DFTLNIHPVEEEDAATYYC	QHSRELPYT	FGGGTKLEIKR
19E9	DFTLNIHPVEEEDAATYYC	QHSRELPYT	FGGGTKLEIRR
10H11	DFTLNIHPVEEEDAATYYC	QHSREFPYT	FGGGTKLEIKR
39G2	DFTLNIHPVEEEDAATYYC	QHSRELPWT	FGGGTKLEITP
35F12	DFTLNIHPVEEGDAATYYC	QHSRELPWT	FGGGTKLEITR
49A10	DFTLNIHPVEAEDATTYYC	QHSRELPLT	FGSGTKLEMKR
34F9	DFTLNIHAVEEEDAATYYC	QHSRELPLT	FGAGTKLELKR
7D7	DFILNIHPVEEEDAATYYC	QHSRELPLA	FGAGTKLELTP
conLC	DFTLNIHPVEEEDAATYYC	QHSRELPYT	
m3-12	DFTLNIHPVEEEDAATYYC	QHSRELP	

Figure 2C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2008/002394

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

   a. type of material
   - [X] a sequence listing
   - [ ] table(s) related to the sequence listing

   b. format of material
   - [X] on paper
   - [X] in electronic form

   c. time of filing/furnishing
   - [X] contained in the international application as filed
   - [X] filed together with the international application in electronic form
   - [ ] furnished subsequently to this Authority for the purpose of search

2. [ ] In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/002394

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/24 A61K39/395 A61P37/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, Sequence Search, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/009526 A1 (BENSON JACQUELINE [US] ET AL) 11 January 2007 (2007-01-11) pages 4,5,7-10; claims 59,60; examples 1-4	1-57
X	CHEN YI ET AL: "Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 116, no. 5, 1 May 2006 (2006-05-01), pages 1317-1326, XP002424834 ISSN: 0021-9738 the whole document	1-10, 14-57

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 July 2008	29/07/2008

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Bernhardt, Wiebke

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/002394

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/052157 A (SCHERING CORP [US]; CHIRICA MADALINE [US]; KASTELEIN ROBERT A [US]; MO) 9 June 2005 (2005-06-09) examples, in particular XIV; pages 7-8	1-57
P,X	WO 2007/027714 A (SCHERING CORP [US]; PRESTA LEONARD G [US]) 8 March 2007 (2007-03-08) claims 1-32; figures 1a-2,c; examples 1-6; tables 1-7; sequences 1-93	1-57
P,X	WO 2007/024846 A (LILLY CO ELI [US]; BEIDLER CATHERINE BRAUTIGAM [US]; BRIGHT STUART WIL) 1 March 2007 (2007-03-01) pages 11-12; claims 1-11; examples 1-5; tables 1,2	1-57
P,X	WO 2007/147019 A (ZYMOGENETICS INC [US]; LEWIS KATHERINE E [US]; PRESNELL SCOTT R [US];) 21 December 2007 (2007-12-21) examples 7,8,10-14,31	1-57
A	WO 2006/068987 A (SCHERING CORP [US]; CUA DANIEL J [US]; KASTELEIN ROBERT A [US]) 29 June 2006 (2006-06-29) examples, claims	1-57
A	HUNTER C A: "New IL-12-family members: Il-23 and Il-27, cytokines with divergent functions" NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 5, 1 July 2005 (2005-07-01), pages 521-531, XP002463443 ISSN: 1474-1733 page 523 - page 524; table 1 reference 54	1-57
A	NESTLE ET AL: "Evidence for a Role of the Interleukin-23 Pathway in the Pathogenesis of Psoriasis" CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 123, 1 January 2007 (2007-01-01), pages S62-S63, XP022076993 ISSN: 1521-6616 abstract	24-26, 49-51

-/--

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169-179, XP004070292 ISSN: 1380-2933 abstract -----	1,2
A	HOLT L J ET AL: "Domain antibodies: proteins for therapy" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484-490, XP004467495 ISSN: 0167-7799 abstract -----	1,2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2008/002394

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
US 2007009526	A1	11-01-2007	NONE			
WO 2005052157	A	09-06-2005	AU	2004293811	A1	09-06-2005
			BR	PI0416211	A	26-12-2006
			CA	2546619	A1	09-06-2005
			CN	1906297	A	31-01-2007
			EP	1699925	A1	13-09-2006
			JP	2008501626	T	24-01-2008
			MX	PA06005676	A	17-08-2006
WO 2007027714	A	08-03-2007	CA	2620802	A1	08-03-2007
			EP	1931710	A2	18-06-2008
WO 2007024846	A	01-03-2007	AU	2006283194	A1	01-03-2007
			CA	2619052	A1	01-03-2007
			EP	1937721	A2	02-07-2008
			KR	20080031450	A	08-04-2008
WO 2007147019	A	21-12-2007	US	2008095775	A1	24-04-2008
WO 2006068987	A	29-06-2006	EP	1853707	A2	14-11-2007